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ABSTRACT

Hong, Yingying. Ph.D., Purdue University, December 2015. Phage Therapy
Applications: Efficacy and Impact On the Gut Microbiome. Major Professors: Alan
Mathew and Paul Ebner.

Phage therapy is a promising antibacterial intervention that has received renewed
interest in recent years. In this study, the antibacterial efficacy of phage treatments was
tested in different food matrices, under different conditions, as well as in both phage
cocktail and single phage forms. Additionally, this study also examined phage genome
sequences, bacterial phage resistance, and the impact of orally administered phages on
acute immune response and gut microbiome of the host in effort to more clearly assess
the safety and long-lasting efficacy of phage-based treatments.
The first study, presented in chapter two, evaluated the efficacy of a three-phage
cocktail in reducing concentrations of E. coli O157:H7 in contaminated ground beef,
spinach, and cheese under various conditions. Additionally, phage resistant E. coli
O157:H7 strains were characterized in terms of phage resistance mechanisms, in vitro
stability of phage resistance, and potential fitness losses. Phage treatments significantly
reduced concentrations of E. coli O157:H7 in ground beef by 1.97 log10 CFU/mL, 0.48
log10 CFU/mL, and 0.56 log10 CFU/mL when treated samples were incubated at room
temperature for 24h, under refrigeration for 24h, or undercooked, repectively. Phage
treatments also reduced concentrations of E. coli O157:H7 in spinach by 3.28 log10
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CFU/mL, 2.88 log10 CFU/mL, and 2.77 log10 CFU/mL when treated samples were
incubated at room temperature for 24h, 48h and 72h, respectively. Phage treatment,
however, did not reduce concentrations of E. coli O157:H7 in contaminated cheese.
Multiple resistance mechanisms were observed. For all three phage resistant E. coli
O157:H7 strains, resistance was stably maintained in vitro throughout a four-day
subculture period in the absence of phage and no significant reductions in bacterial
growth or cell adhesion were observed in resistant strains, indicating that resistance
mitigation strategies may be necessary to optimize phage therapy.
The second study, presented in chapter three, characterized the whole genome
sequences of two E. coli O157:H7 phages used in previous studies. Phages
vB_EcoM_FFH_1 and vB_EcoM_FFH_2 had genome lengths of 108,483 bp and
139,020 bp, respectively. Based on sequence homology, FFH_1 was classified as a T5like phage and FFH_2 was classified as an rV5-like phage. No undesired genes, including
genes coding for antibiotic resistance, toxins, virulence, or lysogeny were observed in
either E. coli phage genomes. However, 108 out of 160 predicted genes in FFH_1 and
163 out of 220 predicted genes in FFH_2 did not match to any genes with characterized
functions in NCBI database.
The third study, presented in chapter four, evaluated the efficacy of a single,
broad-spectrum phage in reducing Salmonella serovars in ground pork and liquid egg.
Phage treatment resulted in significant reduction of Salmonella Typhimurium (ranging
from 0.29 log10 CFU/mL to 1.65 log10 CFU/mL) and Salmonella Enteritidis (ranging
from 0.25 log10 CFU/mL to 1.04 log10 CFU/mL) in ground pork when treated samples
were incubated at room temperature for 24 h and 48 h and under refrigeration for 24h and
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1 wk. Phage treatments also resulted in significant reductions of Salmonella
Typhimurium by 0.49 log10 CFU/mL to 3.14 log10 CFU/mL when treated samples were
incubated at room temperature for 24 h and 48 h and under refrigeration for 24h and 1
wk; however, significant reductions of Salmonella Enteritidis (0.93 log10 CFU/mL and
0.61 log10 CFU/mL) were only observed when treated samples were incubated at room
temperature for 24 h and 48 h. High percentages of phage resistant Salmonella (92.50%
for Salmonella Typhimurium and 50.83% for Salmonella Enteritidis) were observed after
phage treatments at room temperature for 48 h. However, the emergence of phage
resistant Salmonella was only observed in liquid egg.
The last study, presented in chapter five, demonstrated the impact of orally
administrated phages on host acute immune responses and the gut microbiome. Mice
receiving a low amount of phages (105 PFU), a high amount of phages (107 PFU), or a
placebo showed no differences in the levels of intestinal IgA and IgG at either 6 h or 24 h
post treatment. Phage inoculation did elicit some cytokine responses; however, all
cytokine concentrations were within normal ranges for mice at all sampling times across
all treatments. In additional experiments, pigs were treated with basal diet, basal diet
supplemented with antibiotic premix ASP 250, and basal diet with daily inoculation of
5×1010 PFU of phages via oral gavage for two weeks. The gut microbiome of the ileum,
cecum, and feces were characterized using 16S rRNA sequencing. While antibiotic
treatment significantly altered the ileal microbiome compared to the control, no
consistent changes were observed between the phage treated microbiome and the control
microbiome in either the overall microbiome composition or the relative taxonomic
abundance. Relative abundance differences, however, were observed with certain OTUs
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between phage and control microbiomes at three intestinal compartments and further
studies are needed to determine whether these changes are deleterious to host.
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CHAPTER 1. LITERATURE REVIEW

1.1

Foodborne Pathogens And Foodborne Diseases

It is estimated by the US Centers for Disease Control and Prevention (CDC) that,
each year in the US, domestically acquired foodborne pathogens result in 9.4 million
illnesses, 55,961 hospitalizations, and 1,351 deaths (Scallan et al., 2011). Norovirus is the
leading cause of foodborne illnesses, accounting for 58% of the cases, followed by nontyphoidal Salmonella (11%), Clostridium perfrigens (10%), Campylobacter (9%),
Staphylococcus aureus (2.6%), and shiga-toxin producing E. coli (STEC, 1.9%) (Scallan
et al., 2011). Based on the incidences of top 15 foodborne pathogens, which represent
more than 95% of total foodborne illnesses, the US Department of Agriculture (USDA)
estimated an approximate $15.6 million annually, associated with foodborne illness,
namely from health care expenses and wage losses. This estimate, however, does not
include the economic losses of food industry, where a recall of contaminated food can
cost the affected company a direct millions of dollars and its reputation. Therefore, it is in
the interest of both the public and assorted food industries to reduce the contamination of
foodborne pathogens in the foods.
Great effort has been taken to study various foodborne pathogens in terms of their
pathogenesis, prevalence, and transmission. Similar effort has also focused on developing
efficient, yet practical food safety interventions. These studies are the focus of the
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following literature review. As the goal of the accompanying research is to develop
phage therapy as an antibacterial intervention for food safety, the following review will
focus mainly on interventions that target bacterial foodborne pathogens.

1.1.1

Pathogenesis of Major Foodborne Pathogens

Depending on several factors (e.g, etiological agent, pathogenesis, immunity of
the host, etc.), foodborne diseases can be roughly divided into three types: infection,
toxicoinfection, and intoxication. Both infection and toxicoinfection diseases are caused
by ingestion of live pathogens, with the difference that pathogens causing infectious
diseases, such as Norovirus, Salmonella, Campylobacter and Listeria, are invasive to host
tissues, while pathogens causing toxicoinfectious diseases, such as STEC and
Clostridium perfringens, are generally not invasive, but are capable of producing
cytotoxins upon colonization. On the other hand, intoxication refers to diseases caused by
ingestion of foods contaminated with preformed toxins of pathogens. Clostridium
botulinum produced neurotoxin (BoNT), Bacillus cereus produced emetic toxin
(cereulide), and Staphylococcus aureus produced enterotoxin are common causes of
intoxication.
The infective doses for live pathogens in healthy adults can range from a few
hundreds cells, as in the infections of STEC (Tilden et al., 1996) and Campylobacter (M.
H. Kothary, 2001), to more than 105 cells , as in the infection of Salmonella (M. H.
Kothary, 2001). The susceptibility of bacteria to stomach acid affects the level of
infective dose greatly. In STEC O157:H7, an rpos encoded stationary phase sigma factor
mediates acid tolerance response by transforming E. coli cells to stationary phase
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(Gorden and Small, 1993), which explains the low infective dose required by this bacteria.
In intoxication, oral ingestion of several micrograms of toxins per kilogram of host body
weight is sufficient to cause Staphylococcus aureus- and Bacillus cereus-toxins induced
emesis (Shinagawa et al., 1995; FDA, 2012) or as few as nanograms for BoNT of
Clostridium botulinum, (FDA, 2012). Most infective doses are host dependent and
infective doses much lower than those of healthy adults can pose a threat to patients that
are very young, old, pregnant, or immunocompromised (YOPI).
In most cases, patients of foodborne diseases develop relatively mild symptoms,
such as diarrhea, abdominal cramping, and vomiting, and the symptoms are usually selflimiting, lasting only a few days. However, in some cases, especially for the YOPI
population, foodborne diseases can be complicated by much more severe systemic
symptoms, such as hemolytic uremic syndrome (HUS) in STEC infections and meningitis
in Listeria monocytogenes infections. Such complications could lead to organ failure or
death if not treated properly and promptly. Exceptionally high mortality rates are
observed in certain pathogens or particular isolates of pathogens. For example,
foodborne diseases caused by Listeria monocytogenes, Clostridium botulinum, and Vibrio
vulnificus have the highest mortality rates of 15.9%, 17.3% and 34.8%, respectively,
among other major foodborne diseases (Scallan et al., 2011). E. coli O104:H4, the strain
responsible for the massive outbreak in Europe during 2011, harbors virulent genes of
both STEC and EAEC (enteroaggregative E. coli) origins and, therefore, is more
pathogenic than both STEC and EAEC (Muniesa et al., 2012).
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1.1.2

The Transmission and Prevalence of Major Foodborne Pathogens

The term ‘from farm to fork’ identifies farm as the first critical control point of
food safety intervention. Indeed, many foodborne pathogens are carried in farm animals.
Cattle are the primary reservoir of STEC. The prevalence of STEC O157:H7, the most
notable serotype, ranged from 0.3% to 27.3% in beef cattle and from 0.2% to 48.8% in
dairy cattle, and the prevalence of non-O157 STEC ranged from 4.6% to 55.9% in beef
cattle and from 0.4% to 74% in dairy cattle (Hussein and Sakuma, 2005; Hussein, 2007).
Similarly, Salmonella is a prevalent foodborne pathogen in swine and poultry. According
to a previous review, the prevalence of Salmonella ranged from 3.4% to 33% in pigs and
from 5% to 100% in chickens (Foley et al., 2008). In addition to Salmonella,
Campylobacter is also a persistent foodborne pathogen in poultry with its prevalence
ranging from 3% to 90% in broiler chicken flocks before slaughter (Guerin et al., 2010).
Large variation, however, is regularly seen when comparing prevalence studies. This can
due to factors such as farm size, husbandry method, animal age, and sampling time.
Most foodborne pathogens are carried in the gastrointestinal tract of the animals.
Under natural exposure, carriage is generally asymptomatic and it is therefore not
practical to separate infected animals from uninfected ones. Pathogens are shed via feces.
At the pre-harvest stage, the contaminated feces can lead to transmission of pathogens
from infected animals to uninfected ones, contamination of foods harvested on farm (e.g.
raw milk and eggs), contamination of water, and contamination of fresh produce irrigated
with contaminated water. At the post-harvest stage, animal carcasses can be contaminated
via contact with hides/feathers containing fecal matters or via contact with intestinal
content during evisceration.
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In addition to contamination from infected animals, the post-harvest environment
also poses several other high risks to food safety. Pathogens brought by raw materials
(e.g., grains, milk, etc.), insects, rodents, and workers can persist in the environment of
processing plants. A high prevalence of pathogens is frequently associated with conveyer
belts, floor junctions, drains, and sinks, which are difficult to clean and have the high
moisture that is ideal for the formation of biofilms. Listeria is one of the top foodborne
pathogens of concern at the post-harvest stage. The bacteria are widespread, capable of
forming biofilms on the surface of various materials (Chmielewski and Frank, 2003), and
can multiply even under refrigeration. Previous studies have isolated Listeria from both
the environment and equipment of dairy, meat, and vegetable processing facilities
(Chmielewski and Frank, 2003). Studies also observed a high prevalence of Listeria in
post-processing stages, such as deli shops, with a previous study showing that 6.8% of
samples (N=314) collected prior to daily operation from 15 deli shops and 9.5% of
samples (N=4503) collected during operation from 30 deli shops were positive for
Listeria Monocytogenes (Simmons et al., 2014).
The USDA and FDA maintain policies regarding allowed levels of major
pathogens in their regulated food (USDA regulates meat, poultry and processed egg
products and FDA regulates all other foods). In 1994, the USDA Food Safety and
Inspection Service (FSIS) listed STEC O157:H7 as an adulterant in foods, which
authorizes agents to recall food if it is confirmed with O157:H7 contamination. In 2011,
six additional predominant non-O157 STEC groups, including O26, O103, O111, O121,
O45, and O145, were also added to the adulterant list. FSIS has less restrictive rules to
Salmonella and Campylobacter due to their high prevalence and relatively lower
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pathogenicity. According to the updated standards, FSIS established the maximum
acceptable percentages of samples positive of Salmonella and Campylobacter at 9.8%
and 15.7% in broiler carcass, 25% and 1.9% in ground chicken, and 15.4% and 7.7% in
chicken parts, respectively (FSIS, 2015). Currently, no Salmonella standards are available
for pork. On the other hand, Salmonella is considered adulterant in FDA regulated foods,
such as shell eggs. Both FSIS and FDA adopted “zero-tolerance” rule to Listeria in
cooked and ready-to-eat foods.

1.1.3

Challenges of Antibiotic Resistance

Antibiotics have been widely used in livestock and poultry production since
1950’s (Castanon, 2007). They are mainly used at sub-therapeutic levels for growth
promotion and disease prevention and at therapeutic levels for disease treatment. The use
of antibiotics in food animals could potentially reduce the prevalence of foodborne
pathogens in foods (Singer et al., 2007); however, such benefit is greatly compromised by
the emergence of antibiotic resistant bacteria. A handful of studies have highlighted the
connection between the use of antibiotics and the increase of antibiotic resistant bacteria,
both pathogenic and commensal, in agriculture animals (Bager et al., 1997; Aarestrup et
al., 2000; Price et al., 2005). Those bacteria can later be transmitted to humans via food
or animal-human contact and are considered a great threat to human health. Antibiotic
resistant pathogens could lead to human infections that are less responsive to antibiotic
treatment; and they could also spread antibiotic resistance genes to antibiotic susceptible
bacteria via horizontal gene transfer. In 2013, CDC estimated that infections associated
with antibiotic resistant bacteria and fungi lead to more than 2 million illnesses and
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23,000 deaths annually in the US (CDC, 2013). Because agriculture use of antibiotics
contributes to the majority of antibiotic sales in US, proposals for greater restriction and
regulation are common. In 2013, the FDA implemented a Guideline for Industry to phase
out the use of certain medically important antibiotics for growth promoters while
requiring veterinary supervision for all agriculture use of antibiotics (FDA, 2013). Based
on the previous experience of antibiotic bans in Europe, several groups predict a
consequent increase of disease susceptibility may be observed in particularly young
animals, which is economically concerning and could potentially be a food safety issue
due to the fact that animals at their less optimized health status can be more susceptible to
the infection of foodborne pathogens (Singer et al., 2007). Therefore, effective
alternatives of antibiotic treatment are greatly needed.

1.1.4

Food Safety Interventions

A quantitative risk assessment predicted that a 2-log reduction of Campylobacter
in chicken carcass could lead to a 30 fold reduction of Campylobacteriosis associated
with the consumption of chicken (Rosenquist et al., 2003). This study clearly
demonstrated the relationship between successful on-farm control of foodborne
pathogens and an effective reduction of foodborne illnesses in humans. On-farm control
of foodborne pathogens could be addressed in three ways: 1) limiting environmental
exposure to insects, rodents, vehicles, and visitors that potentially carry foodborne
pathogens; 2) increasing host resistance to pathogen infections; and 3) using
antimicrobial agents to reduce the levels of pathogens in infected animals (Lin, 2009).
Based on such consideration, several common food safety interventions include
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vaccination, supplementation with prebiotics and probiotics, and phage therapy. The
applications of phage therapy will be discussed in detail in the second part of the
literature review.
Vaccination is an effective approach to enhance the resistance of animal hosts to
pathogen infection. Although many foodborne pathogens are commensal bacteria to the
host, the presence of these pathogens often elicits both host systemic and mucosal
immune responses, which can, in turn, reduce the levels of the pathogens in animal
intestine and, therefore, provide the fundament for vaccine development (Lin, 2009). A
successful vaccination for the use in livestock and poultry production is expected to be
not only effective, but also cross protective, easy to apply as massive immunization, and
cost-efficient. Currently, most animal vaccines are attenuated vaccines, inactivated
vaccines, or subunit vaccines. There are several commercially available Salmonella
vaccines for poultry and swine and two STEC O157:H7 vaccines for cattle. Studies have
shown the efficacy of these vaccines in preventing or reducing pathogen colonization to
various extents, with some reduction only observed in certain organs or under certain
experimental setting (Desin et al., 2011; Wileman et al., 2011). More throughout
characterization of immunogenic components of the pathogens as well as the
development of novel adjuvants and vaccination technologies, such as DNA vaccines and
vector vaccines, may lead to more effective and consistent vaccination regimes.
Additionally, for broilers particularly, vaccination can be challenging due to their short
life span of approximately 5-7 weeks and the high cost associated with individual bird
vaccination. Such challenges might be addressed using in ovo injection techniques, which
enables delivery of vaccine into eggs at a speed of 70,000 eggs/hour (Desin et al., 2013).
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While in ovo techniques are widely used in vaccination against viral diseases, their
application to bacterial vaccines remains to be developed.
Restriction in growth promoting antibiotics (and possibly also prophylactic
antibiotics in the near future) opens the market for probiotics and prebiotics. Probiotics
are microorganisms that can provide beneficial effects to animals and humans when
consumed in sufficient amounts. Most of the probiotic strains belong to Lactobacillus and
Bifidobacterium. While the mechanisms of probiotics in promoting animal health are not
fully understood, their ability to reduce foodborne pathogens is likely due to their
antimicrobial effect, competitive exclusion, and stimulation of host immune system
(Callaway et al., 2008). A Lactobacillus acidophilus-based probiotic was previously
reported by several independent studies to reduce the prevalence of STEC O157:H7 in
feces and hides of cattle (Brashears et al., 2003; Younts-Dahl et al., 2004; Stephens et al.,
2007). This probiotic was also observed to increase growth efficiency and is therefore
widely used in US and Canadian cattle feedlots. Similarly, various probiotics were also
tested in chicken and swine and shown to be effective in reducing Salmonella (Pascual et
al., 1999) and Campylobacter (Ghareeb et al., 2012). Prebiotics, on the other hand, are
organic compounds that are generally indigestible to animal hosts, however, they can be
digested and utilized by specific beneficial bacteria populations in hind gut, and therefore
provide competitive advantages to these bacteria. For example, previous studies (Courtin
et al., 2008; Jung et al., 2008) have shown that the inclusion of several oligosaccharides,
such as xylooligosaccharides, arabinoxylooligosachrides, and galactooligosaccharides, in
chicken feed lead to increased levels of Bifidobacterium, which is an indigenous
commensal bacteria known to act antagonistically against pathogens. Probiotics and
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prebiotics are sometime used together for synergistic effect (Tanner et al., 2014).
However, inconsistencies in the efficacy of probiotics and prebiotics are commonly
observed. The failed treatments could be partly due to poor adaptation or colonization of
probiotic strains or prebiotic-selected strains in the designated animal gut environments.
Coupling with advanced molecular biotechnologies in profiling the gut microbiome may
produce more consistent and effective probiotics and prebiotics.
Besides pre-harvest interventions, post-harvest food safety interventions are
equally important. It is critical for each processing plant to conduct and maintain Good
Manufacturing Practices (GMP) as well as HACCP programs. Additionally, the use of
phage therapy (Guenther et al., 2012; Hong et al., 2014), organic acids (Castillo et al.,
2001; Park et al., 2011), and irradiation (O’Bryan et al., 2008; Kudra et al., 2011) have
shown promising results in reducing the level of foodborne pathogens at post-harvest
stages. It should also be noted that no single antimicrobial intervention could perfect the
task of eliminating foodborne pathogens. Integration of multiple interventions often
results in collective or even synergistic reductions and further studies should be
conducted to optimize such effects.
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1.2

Phage Therapy

Bacteriophages, or phage, are natural predators of bacteria that present
ubiquitously in the nature. The discovery of phages dates to the 1910’s, where two
microbiologists, Frederick Twort and Felix d’Herelle, independently reported an antibacterial phenomenon caused by virus-like organisms. These organisms were later named
‘bacteriophage’ (‘bacteria-eater’ in Greek). Shortly after their discovery, the therapeutic
potential of phages was explored worldwide. Phage therapy showed promising results in
prevention and treatment of dysentery, cholera, typhoid fever, and skin infections (Kutter
and Sulakvelidze, 2004). However, in western countries, phage therapy was soon
overshadowed and replaced by the discovery and widespread use of antibiotics, which
have better consistency and broader spectrum. In contrast, phage therapy was continued
in Eastern Europe. The Eliava Institute in Georgia (part of former Soviet Union) and
Polish Academy of Science are the two most renowned institutions in the area of clinical
phage applications.
In recent years, there has been renewed interest in phage therapy worldwide,
especially as phages are viewed as promising weapons against antibiotic resistant bacteria.
The efficacy of phage therapy has been widely evaluated for application in human
medicine, veterinary medicine, food safety, and environmental sanitation. Compared to
other antimicrobials, phages offer unique advantages of targeting bacteria with high
specificity, while being natural and self-limiting.
Based on life cycles, phages can be classified into lytic phages and temperate
phages. Lytic phages lyse bacterial cells immediately after phage proliferation, while
temperate phages integrate into the bacterial genome upon infection and replicate as a
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part of bacterial genome until excision is induced. It is not uncommon that a part of
bacterial genome is packed into a new phage during the excision of temperate phages. To
avoid horizontal gene transfer associated with such inaccurate excision, obligate lytic
phages are usually preferred in phage therapy.
The mechanism of phage therapy starts with the adsorption of phages to bacterial
host cells. The host ranges of phages are commonly limited to certain bacterial species or
sub-species (Loc-Carrillo and Abedon, 2011). Such specificity is facilitated by interaction
between phage tail fiber proteins and corresponding bacterial receptors. Phage nucleic
acid is then injected into bacterial cells. Early genes in the phage genome are expressed
immediately after injection to hijack host machinery for the expression of middle and late
genes, which are involved in nucleic acid replication and protein synthesis. Following the
assembly of new functional phages, phage proteins, such as endoysin and holing in grambacteria and lysine in gram+ bacteria, lyse the bacterial cell and enable the release of new
phages for further infection of new hosts.
While the mechanism is straightforward, the practical application can be
complicated. Issues such as the incomplete annotation of phage genomes, development of
phage resistance, and understudied impact of phage therapy on host immune responses
and gut microbiome remain to be addressed.

1.2.1 Pre-harvest Phage Applications
Phage has been applied at both pre-harvest and post-harvest stages to prevent or
reduce various foodborne pathogens. At the pre-harvest stage, the efficacy of phagebased applications has been extensively studied against predominant foodborne
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pathogens in swine, chicken, cattle, and others. The animal gastrointestinal (GI) track, as
the essential colonization site of many major foodborne pathogens, is the main target site
in aforementioned studies. However, due to the complex physiological and
microbiological environment in GI track, the in vivo efficacy of phage applications is less
predictable compared to that of in vitro studies.
The presence of stomach acid (Dabrowska et al., 2005) and certain proteolytic
enzymes (Northrop, 1964) is the primary concern when phages are administered orally.
Phage viability is greatly impaired (Koo et al., 2001; Zhang et al., 2015) under extreme
acidic condition due to denaturation of phage structure proteins that play essential roles in
the protection of phage genetic material and recognition of bacteria host. To address such
problems, protection manners, such as microencapsulation and buffering, are commonly
applied. Wall et al. (Wall et al., 2010) demonstrated the efficacy of a microencapsulated
phage cocktail to reduce experimentally infected Salmonella Typhimurium in small pigs.
A phage cocktail protected in alginate-oil microspheres was able to reduce Salmonella in
tonsils, ileum, and cecum by 2 to 3 log after phage treatment every 2 h for 6 h. In terms
of buffering, in one study, pig stomach acid was neutralized with sodium bicarbonate
prior to the treatment of E. coli phages. Compared to control pigs where no phage was
detected in feces, pigs that were pre-treated with sodium bicarbonate consistently yielded
phages at levels of 1.5 x 106 to 7 x 103 PFU per gram feces during 3 days post phage
treatment, indicating pre-neutralization of stomach acid increased numbers of viable
phages that could reach the intestine (Jamalludeen et al., 2009). For application in
chickens, due to smaller volume of chicken stomach, phage solution containing antiacid
could provide sufficient protection. As reported previously, Salmonella phages that were
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suspended in phosphate buffered saline containing 30% CaCO3 showed effective
reduction of both Salmonella Enteritidis and Salmonella Typhimurium in broiler chickens
(Atterbury et al., 2007).
Alternatively, to avoid the contact with stomach acid, other delivery routes have
been evaluated. Previously, the reduction of E. coli O157:H7 in feces was compared
among steers receiving phages via oral, rectal, oral + rectal administrations and control.
Rectal or oral + rectal administration did not elicit any superior bacterial reduction effect,
probably due to a short retention time of phages in the rectum (Rozema et al., 2009).
Additionally, phages have been delivered by aerosol-spray to target bacteria on livestock
hides, chicken feathers, and farming environment. A previous study demonstrated that
phage treatment via aerosol-spray in young chicks effectively prevented the incidence of
Salmonella Enteritidis infection in that population by nearly 30% (Borie et al., 2008). A
phage-based aerosol spray to reduce STEC O157:H7 in cattle hide before slaughter is
also commercially available (Goodridge and Bisha, 2011).
Besides phage delivery methods, the selection of appropriate treatment time
points is equally important to the outcome of pre-harvest phage therapy. Several studies
reported transient reduction of foodborne pathogens in response to phage treatment in
animals (Berchieri et al., 1991; Chase et al.,2005; Loc Carrillo et al., 2005). Chase et al.
(Chase et al., 2005) reported that a treatment with a 37-phage cocktail in cattle resulted in
significant decrease of STEC O157:H7 in ileum and cecum initially. However, such
reduction was compromised by the regrowth of targeted bacteria a few hours post
treatment. No phage resistant bacteria were detected throughout the experiment; instead,
authors reported an associated decrease of phage concentration, indicating that transient
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reduction could be a collective result of phage self-limiting and bacteria re-infection. The
use of phage in combination with other antimicrobials, such as competitive exclusion
bacteria, might be effective to prevent such transient reduction (Goodridge and Bisha,
2011). In some studies, especially those using single phage treatment, the emergence of
phage resistant bacteria was observed (Loc Carrillo et al., 2005; Atterbury et al., 2007).
The presence of phage resistant bacteria could also contribute to transient reduction of
targeted bacteria. Furthermore, phage resistant bacteria could hamper the efficacy of
additional phage application if the administration design uses multiple treatments.
Considering the occurrence of bacterial regrowth and phage resistance, it is generally
suggested that pre-harvest phage therapy is more effective when applied before animals
are slaughtered.

1.2.2 Post-harvest Phage Applications
Phage applications at post-harvest stage are generally expected to be more
effective than those in pre-harvest stage. The post-harvest environment is less dynamic or
complex than the GI track of live animals, however, the intrinsic properties of foods (e.g.
composition, pH and water content) and conditions associated with food processing (e.g.
temperature, chlorinated water and UV) could affect the efficacy of phage applications
(Zhang et al., 2015) and should be carefully considered during the development of postharvest phage applications.
Phage applications have been tested in various foods, including meat, fresh
produce, dairy products, and processed foods. Guenther et al. (Guenther et al., 2009)
measured the efficacy of phages to reduce experimentally contaminated Listeria
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monocytogenes strains in a variety of ready-to-eat foods. Phage applied at a high dosage
rapidly reduced Listeria counts to undetectable levels in liquid foods and by up to 5 log
CFU in solid foods after treatment at 6 °C for 6 days. Similarly, the use of a Salmonella
phage cocktail resulted in significant reduction of Salmonella Enteritidis by 2.5 log to 3.5
log in fresh honeydew melon slices incubated at 5 °C, 10 °C, and 20 °C. No bacterial
reduction, however, was observed when using the same phage cocktail on apple slices.
The more acidic pH of apple slices was noted as the likely main reason reduced efficacy
(Leverentz et al., 2001). On the other hand, Hong and colleagues (Hong et al., 2014)
reported a temperature effect on the efficacy of phage application in ground beef. The
three-phage cocktail used in the study reduced the levels of STEC O157:H7 by 1.97 log
CFU/mL after treatment for 24 h at room temperature (24 °C). In contrast, a reduction of
only 0.48 log CFU/mL was observed under refrigeration (4 °C) for 24 h. This was likely
due to both bacteria and phage activity being inhibited at lower than optimal growth
temperatures.
Other studies also evaluated the potential of phages to sanitize bacterial
contamination in food processing equipment and environments. Some foodborne
pathogens, such as Listeria and Campylobacter, can be persistent in food processing
plants by forming biofilms at both food-contact (e.g. slicing blades and conveyer belts)
and non-food-contact surfaces (e.g. floor drains and floor-wall conjunctions). A previous
study showed that the use of a broad-spectrum phage significantly reduced Listeria cell
counts in biofilms formed in plates and on stainless steel coupon surface (Soni and
Nannapaneni, 2010). The same study also pointed out that older biofilms with multilayer
structures were less susceptible to phage treatment. The formation of extracellular

17
polymeric substances (EPS) matrix is a main characteristic of biofilm. Older biofilms
generally have more complex EPS matrices, which are a large barrier for efficient
delivery of phages within biofilms. While it is difficult to isolate a natural phage that is
both bacteria-specific and contains an EPS-degrading enzyme, phages can be engineered
to express EPS-degrading enzymes and such genetic modification significant improved
the efficiency of biofilm removal as described in a previous study (Lu and Collins, 2007).

1.2.3 Phage Genome Characterization
Driven by the interest in phage therapy, there is a remarkable increase in the
number of completely sequenced phage genomes. At the time of writing, there are 1536
unique phage genomes in NCBI genome database. The majority of these phage genomes
are dsDNA with a small subset of genomes being ssDNA, dsRNA, and ssRNA. In terms
of size, predominant phage genomes generally fall into one of the three ranges, which are
less than 10kbp, 30-50kbp and 100-200kbp (Hatfull, 2008).
The annotation of phage genomes is a necessary characterization of phages for
many reasons. Firstly, it facilitates more comprehensive understanding of phage infection
at the genetic level by identifying genes involved in host recognition, phage genome
replication, structural protein expression, and bacterial lysis. Secondly, with comparative
genomics, new insights into phage evolution can be provided. Lastly, the identification of
undesired genes, such as those conferring antibiotic resistance, lysogeny, toxins, and
allergens, is required as an essential safety evaluation during phage commercialization.
Despite a rapid increase in the number of available phage genomes and the recent
advance in bioinformatic analysis, information on characterization of full phage genome
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sequences is still lacking. As a result, most published phage genomes contain very large
sections of hypothetical genes with no predicted functions. This is true even in the T4
phage genome, one of the most well-characterized phage genomes, where nearly half of
the T4 genes are yet to be characterized (Miller et al., 2003). Further annotation of the
large unknown sections could provide more precise characterization of phages both
biologically and in terms of safety, and protect against the spread of undesired genes.

1.2.4

Phage Resistance

During the co-existence of bacteria and phages, a sub-group of bacteria often
develop phage resistance mechanisms in order to preserve bacterial lineages. This is an
unintended, however, inevitable phenomenon of phage therapy. Phage resistance is
considered one of the major hurdles that may limit phage therapy being widely applied.
The emergence of phage resistant bacteria can be observed in hours to days in phagebacteria co-incubations in media or in phage treatments of experimentally contaminated
foods and animals, especially when a single phage is used.
The mechanisms of phage resistance can be summarized into several categories,
including prevention of adsorption, prevention of phage nucleic acid entry, nucleic acid
degradation, and abortive infection system (Labrie et al., 2010). Adsorption is the first
step of phage infection and is facilitated by phages binding to bacterial receptors. To
escape phage adsorption, bacteria undergo conformational modification of receptors
(Nordström and Forsgren, 1974; Riede and Eschbach, 1986; Bohannan and Lenski, 2000;
Morita et al., 2002), production of extracellular matrix (Mizoguchi et al., 2003), and
competitive binding of receptors (Destoumieux-Garzón et al., 2005). Preventing the entry
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of phage nucleic acid is mainly reported in superinfection exclusion. In T4 phage
infection, phages that have successfully infected bacteria produce two proteins, Imm and
Sp, which provide resistance to host bacteria to further infections by the same phage. This
is facilitated by Imm-induced conformational change of phage nucleic acid injection sites
and Sp-mediated inhibition of phage lysozyme activity (Lu and Henning, 1994).
Additionally, many bacteria possess a restriction-modification (R/M) system for
degradation of foreign nucleic acid. For example, the R/M system can recognize and
degrade foreign nucleic acid that is not properly methylated. CRISPR (clustered regularly
interspaced short palindromic repeats)-Cas is another host system that targets phage
nucleic acid (Horvath and Barrangou, 2010). The cas-encoded endonuclease inactivates
phages by cleaving phage genomes at a site that shows homology to spacer sequences
contained in CRISPR region. CRISPR-Cas system can also foster resistance to new
phages by acquiring sequences of the phages as new spacers during infection. Finally,
some infected bacteria undergo cell apoptosis via abortive infection systems to interfere
with phage propagation (Dy et al., 2014).
Based on our current knowledge, it remains difficult to evaluate the impact of
phage resistance to various phage applications. Several studies demonstrated that the
development of phage resistance could lead to fitness loss in resistant mutants, rendering
them less virulent or less growth competitive. In a phage treatment to reduce
Campylobacter jejuni in broiler chickens, Scott and colleagues isolated a group of phage
resistant mutants, which, compared to the original susceptible strain, could not effectively
colonize the intestinal epithelium of broiler chickens and showed reversion to phage
susceptible phenotype when reintroduced to chicken intestine in the absence of phages
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(Loc Carrillo et al., 2005; Scott et al., 2007). Consistent with this study, the loss of phage
resistant phenotype was also reported when continuously culturing phage resistant
Salmonella mutants in vitro in the absence of phages (Atterbury et al., 2007). Meanwhile,
growth competitiveness was measured in phage resistant Pseudomonas fluorescens
mutants, which showed 36% less competitive than phage susceptible strains when grown
in soil (Gómez and Buckling, 2011).
One feature that differentiates phage resistance from many other anti-bacterial
resistances is the potential of phages to circumvent phage resistance. Such phenomena
can be observed in a continuous bacteria-phage coincubation (Mizoguchi et al., 2003).
While it is theoretically possible that phage mutants can always be isolated to treat
bacteria with phage resistance, practically, the cost for characterization, the requirement
of new regulatory approval make continual replacement of phages impractical.
Using a phage cocktail of multiple distinct phages is one of the most practical and
effective strategies to avoid or delay the development of phage resistance. Compared to
the use of a single phage, a bacterium is much less likely to simultaneously develop
multiple, unrelated resistance mechanisms against all phages in the cocktail. However,
the expense of characterization, regulation approval and production increases with the
increase in number of phages in cocktail. Therefore, a fine balance between the
complexity of phage cocktail and the development expense must be obtained. In addition,
previous studies also suggested rotation of several phage cocktails in order to optimize
the efficiency of a long-term phage treatment.
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1.2.5 Animal Gut Microbiome
The animal GI tract harbors a diverse population of microorganisms. For example,
approximately 800 microbial species were identified in swine gut (Looft et al., 2012).
Collectively, these gut microorganisms are called the gut microbiome, which has been
long known to play an important role in both the growth and health of animals.
The gut microbiome serves as a natural defense against opportunistic pathogens
by competitive exclusion and production of antimicrobial compounds. Metabolically, the
gut microbiome helps extract energy from host-indigestible feed ingredients. This is
evidenced by the fact that conventional raised mice require 30% less calorie intake than
germ-free mice to maintain the same body weight (Wostmann et al., 1983). Meanwhile,
many microbial by-products are essential nutrients to host, such as vitamin K, short-chain
fatty acids, and growth factors. Short-chain fatty acids, for example, are the preferred
nutrients of colonic epithelial cells and, therefore, are important in colonic development
and integrity (Cook and Sellin, 1998). It is commonly observed that germ-free animals
have systemic immune defects at tissue, cellular and molecular levels, with, for example,
underdeveloped gut-associated lymphoid tissues, fewer CD4+ and CD8+ T cells, and
diminished expression of secretory intestinal IgA (Round and Mazmanian, 2009). These
defects can be corrected to certain levels by colonization with commensal gut
microorganisms (Mazmanian et al., 2005; Chinen and Rudensky, 2012), indicating the
importance of gut microbiome in shaping host immune system.
Among many factors that perturb gut microbiome, the supplementation of subtherapeutic antibiotics has been extensively studied. Many studies have shown that subtherapeutic levels of antibiotics in feed influence gut microbiome of agriculture animals
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(Collier et al., 2003; Dumonceaux et al., 2006; Looft et al., 2012). However, the
consequences are two-sided. On one hand, it is generally considered that feeding
antibiotics could reduce gut microbial load, which, consequently, reduces the nutrients
utilized by microbial metabolism as well as the energy expended by the immune system
to maintain microbiome homeostasis, and, therefore, leads to growth promotion. With the
help of metagenomic sequencing of the gut microbiome, it is also noticed that antibiotictreated gut microbiome had increased number of genes associated with energy production
and conversion (Looft et al., 2012), which further illustrates how antibiotics could impact
growth. However, the benefit of antibiotics comes at a cost. As expected, feeding
animals with sub-therapeutic antibiotics significantly increases the abundance and
diversity of antibiotic resistant genes in the gut microbiome (Looft et al., 2012).
Population shifts are also observed (Kim et al., 2012; Looft et al., 2012; Lin et al., 2013).
Previously, Lin et al. reported that the ileal microbiome of chickens fed with tylosin had
significantly lower abundance of Lactobacillus spp. than ileal microbiome of antibioticfree animals (Lin et al., 2013). Looft et al. showed that pigs receiving a diet with
antibiotic premix ASP 250 have increased abundance of E. coli along with members of
Succinivibrio and Ruminococcus genera and decreased abundance in members belonging
to the genera of Anaerobacter, Barnesiella, Papillibacter, Sporacetigenium, and Sarcina
in fecal microbiome comparing to control pigs (Looft et al., 2012). Whether and how the
abundance decrease or increase of specific microorganism is deleterious to host is still
largely unknown. However, studies with higher dosages of antibiotics indicated that
antibiotic-induced microbiome alteration was associated with reduced expression of
antimicrobial peptides, downregulation of genes involved in antigen presentation, and
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deficient T cell differentiation and activation in animals (Willing et al., 2011). Such an
environment could lead to increased susceptibility to infections as increased colonization
with Clostridium difficile and vancomicin-resistant Enterococcus has been frequently
documented in antibiotic-treated patients.
Compared to antibiotics, one advantage of phages is their high host specificity. It
is common for phages to only infect strains within a bacterial species and, much less
commonly, some closely related bacterial species (Loc-Carrillo and Abedon, 2011).
Therefore, it is commonly considered that phage treatment have little collateral effect on
untargeted commensal bacteria (Loc-Carrillo and Abedon, 2011; Ghannad and
Mohammadi, 2012). However, such a statement lacks the support of experimental
evidence, especially any evidence based on culture-independent studies. There is, to the
best of author’s knowledge, one paper demonstrating the effect of a E. coli phage cocktail
on healthy human gut microbiome via 16S rRNA sequencing and the study showed no
consistent changes or differences between fecal microbiome of individuals that received
oral-administered phages and a placebo (Sarker et al., 2012). No studies have
demonstrated the lack of effect on untargeted gut microbiome when phages are used in
agriculture animals. There are several factors that may differentiate the effect of phage
treatments on gut microbiome of agriculture animals from that of human, such as phage
products designed for agriculture usage may have broader target spectrum for the ease of
uses as presumptive treatments and many phage-targeted bacteria in agriculture animals
are commensal bacteria to the host. Therefore, it is also meaningful to evaluate the effect
or lack of effect of phage treatments on gut microbiome of various agriculture animals.
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1.2.6

Phage Commercialization and Its Hurdles

Currently in US, the availability of commercialized phage products is limited for
food safety. In pre-harvest stage, phage products are available as hide sprays to reduce
STEC O157:H7 in cattle or feather washes to reduce Salmonella in chickens prior to
slaughter (Goodridge and Bisha, 2011). More phage products are available at the postharvest stage for the decontamination of foods and food processing facilities that have
high risk of contamination with STEC O157:H7, Salmonella, and Listeria monocytogenes.
Several of the post-harvest phage products have GRAS (Generally Recognized As Safe)status and can be used in ready-to-eat foods; and several are OMRI (Organic Materials
Review Institute)-listed and can be used in organic products.
Despite the value of phage therapy to combat antibiotic resistant bacteria and the
successful examples of using phage to treat bacterial infections in human and animals in
Eastern Europe, the therapeutic phage applications remain limited in western countries.
Several research hurdles for therapeutic phage applications include, but are not limited to:
1) a lack of understanding of in vivo phage distribution and phage receptor expression; 2)
the difficulty in measuring phage pharmacokinetics; and 3) insufficient understanding of
the impact of phage resistance and the safety of in vivo phage treatments (Verheust et al.,
2010; Tsonos et al., 2014). Additionally, the regulatory framework of western countries
poses a significant hurdle for therapeutic phage applications. Phage therapy is currently
under the regulation of FDA using a draft protocol adapted from the traditional antibiotic
regulatory protocols. The current protocol requires each phage of the phage cocktail to
undergo individual clinical trials and requires re-approval of products if the composition
of phage cocktail is altered (Thiel, 2004). However, this protocol fails to address the
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unique nature of phage therapy and more appropriate approaches for phage therapy
regulation should be identified.
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1.3

Goal of The Projects

The first goal of this study was to determine whether phage-based approaches
could effectively reduce STEC O157:H7 and Salmonella in various experimentally
contaminated food matrices. In addition, the second goal was to characterize the factors
that could affect the efficacy and safety of phage-based methods, namely the
development of phage resistance and the potential impact of phage application on host
acute immune responses and gut microbiome. By achieving those goals, we expected to
comprehensively evaluate the potential of phage therapy as an antibacterial approach for
applications in animals and foods.
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CHAPTER 2. DEVELOPMENT OF BACTERIOPHAGE TREATMENTS TO
REDUCE ESCHERICHIA COLI O157:H7 CONTAMINATION OF BEEF
PRODUCTS AND PRODUCE

2.1

Abstract

E. coli O157:H7 remains a foodborne pathogen of concern with infections
associated with products ranging from ground beef to produce to processed foods. We
previously demonstrated that phage-based technologies could reduce foodborne pathogen
colonization in live animals. Here, we examined if a three-phage cocktail could reduce E.
coli O157:H7 in experimentally contaminated ground beef, spinach, and cheese. The
three phages were chosen from our E. coli O157:H7 phage library based on their distinct
origins of isolation, lytic ranges and rapid growth (40- to 50-min life cycle). Two phages
belonged to the Myoviridae family and the other phage belonged to the Siphoviridae
family. The phage cocktail was added to ground beef, spinach leaves and cheese slices
contaminated with E. coli O157:H7 (107 CFU) at a multiplicity of infection of 1. Phage
treatment reduced (P<0.05) the concentrations of E. coli O157:H7 by 1.97 log10 CFU/mL
in ground beef when stored at room temperature (24 °C) for 24 h, 0.48 log10 CFU/mL at
refrigeration (4 °C), and 0.56 log10 CFU/mL in undercooked condition (internal
temperature of 46 °C). Likewise, phage treatment reduced (P<0.05) E. coli O157:H7 by
3.28 log10 CFU/mL, 2.88 log10 CFU/mL, and 2.77 log10 CFU/mL in spinach when stored
at room temperature for 24 h, 48 h and 72 h, respectively. Phage treatment, however, did
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not reduce E. coli O157:H7 concentrations in contaminated cheese. Additionally, three
phage resistant E. coli O157:H7 strains [309-PR (phage resistant) 1, 309-PR4, and 502PR5] were isolated and characterized to test if phage resistance could limit long-term use
of phages as biocontrol agents. Growth kinetics and adsorption assays indicated that
phage resistance in strains 309-PR4 and 502-PR5 was mediated, at least in part, by
prevention of phage adsorption. Phage resistance in strain 309-PR1 was the result of
limited phage proliferation. Phage resistance was stably maintained in vitro throughout a
four-day subculture period in the absence of phage. No significant reductions in bacterial
growth or cell adhesion were observed in resistant strains. Taken together, our results
provide additional support for the use of phage to control E. coli O157:H7 in food
products; however, the emergence of phage resistant bacteria could limit the efficacy of
phage products. Therefore, further studies are needed to develop resistance mitigation
strategies to optimize phage-based technologies.
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2.2

Introduction

The foodborne pathogen, E. coli O157:H7, is a well-known Shiga-toxin
producing bacterium that caused more than 63,000 illnesses, 2,138 hospitalizations, and
20 deaths in the U.S. in 2011 (Scallan et al., 2011). Ruminants are the main reservoirs.
The bacterium predominantly colonizes the recto-anal junction of cattle and is passed to
the environment through feces (Grauke et al., 2002), which often contaminate hides,
drinking water, and pen barriers leading to rapid transmission among housed cattle
(McGee et al., 2004). The pathogen can then be transferred to carcasses during
processing resulting in contaminated meat products. Traditionally, many human
infections have been associated with undercooked contaminated meat products,
particularly ground beef; however, contaminated fresh produce and other ready- to-eat
and processed foods are increasingly associated with E. coli O157:H7 infections (Rangel
et al., 2005).
The use of bacteriophage-based technologies to control foodborne pathogen
transmission has received more attention in recent years. Phages have the advantages of
being easy to isolate and very specific for targeted bacteria (Loc-Carrillo and Abedon,
2011). Currently, only a limited number of studies have examined the efficacy of phages
to limit E. coli O157:H7 contamination of food products (Sharma et al., 2009; Viazis et
al., 2011; Hudson et al., 2013). In this study, we aimed to determine whether phage-based
treatments could effectively limit pathogen contamination in food products. We isolated
wild-type E. coli O157:H7 phages and characterized them to identify phages with
optimum host-ranges and in vitro kinetics. Three potential phages were further tested for
their ability to limit E. coli O157:H7 contamination in ground beef, spinach, and cheese.
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Finally, we examined the development of phage resistance to determine whether this
phenomenon could limit the long-term use of phages as biocontrol agents.
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2.3

Materials And Methods

2.3.1 Bacteria and Bacteriophages
Sixteen E. coli O157:H7 phages were isolated from different wastewater
treatment plants located throughout Indiana using a method described previously (Wall et
al., 2010). Each phage was tested for its lytic ability against a panel of 48 distinct (i.e.,
individually typed and collected from various laboratories, outbreaks, animals, food
sources) E. coli O157:H7 isolates by standard plaque assay, as described previously
(Wall et al., 2010). From this collection, three phages, vB_EcoS_FFH_1 (FFH1),
vB_EcoM_FFH_2 (FFH2) and vB_EcoS_FFH_3 (FFH3), from three geographically
distinct locations and each showing broad lytic ranges (i.e., ability to lyse > 95% of test
isolates) were chosen for challenge experiments described below.

2.3.2 Bacteriophage Kinetics
Single-step growth curves were generated for each phage to measure their lytic
cycles using a protocol described previously (Ellis and Delbruck, 1939) with
modifications. Briefly, individual phages were mixed with 500 µL of freshly prepared E.
coli (108 CFU/mL; strain 309) at a multiplicity of infection (MOI) of 1. The mixture was
incubated at 37 °C for 1 min to allow phage adsorption and then centrifuged at 10,000 ×
g for 30 s. The pellet containing phage- adsorbed bacteria was resuspended in 1 L Luria
Bertani (LB, Becton, Dickinson and Company, Franklin Lakes, NJ) broth containing logphase growth E. coli O157:H7. Samples were collected at 5 min intervals for 1.5 h. Onehalf of each sample was treated with chloroform (Mallinckrodt Pharmaceuticals, St.
Louis, MO) to quantify assembled phages, whereas the other half was left untreated to
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quantify the phages as infective centers. Phages in each sample were quantified by
standard plaque assay in duplicate. Eclipse period was determined from the curve of
assembled phages, whereas latent period and burst size were determined from the curve
of infective centers.

2.3.3

Transmission Electron Microscopy (TEM)

Phages were concentrated using a polyethylene glycol-8000 precipitation method,
as described by Sambrook et al. (1989). Concentrated phage stocks were then
characterized by transmission electron microscopy (TEM) at the Purdue Life Science
Microscopy Facility (West Lafayette, IN) based on basic morphology including size, tail
structure and head structure. The phage sample was carried on a mesh copper grid with
carbon-coated formvar film and negative stained by 2% uranyl acetate. Images (92,000 ×
magnification) were collected by a FEI/Philips CM-100 TEM, as described previously
(Wall et al., 2010).

2.3.4

Phage Treatment of E. coli O157:H7 Contaminated Food Products

The phage cocktail used in each treatment was a mixture of three wild-type E. coli
O157:H7 phages, FFH1, FFH2, and FFH3, chosen based on in vitro host-range and
growth kinetics. The three phages were mixed in equal amounts and the final
concentration of the phage cocktail was adjusted to 108 PFU/mL. For challenge studies, E.
coli O157:H7 strain 309, isolated from a beef feedlot, was fluorescently labeled via
transformation using a green fluorescent plasmid (pGFP; Clontech, Mountain view, CA).
All food samples tested in this study were purchased from local retail outlets.
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Phage treatment of contaminated ground beef was tested under three conditions:
room temperature (n = 10/treatment, 20 g/sample), refrigeration (n = 16/treatment, 20
g/sample), and undercooking (n = 10/treatment, 40 g/sample). For phage-treated samples,
individual ground beef samples were simultaneously inoculated with GFP-expressing E.
coli O157:H7 at a ratio of 5 × 105 CFU/g sample and the phage cocktail at an MOI of 1.
Samples receiving E. coli O157:H7 but no phage served as controls. For room
temperature and refrigerated conditions, samples were incubated at room temperature and
4 °C, respectively, for 24 h. To study the phage treatment under undercooked conditions,
both phage-treated and control samples were equally divided into two groups, where they
were cooked to an internal temperature of 63 °C (i.e., the USDA recommendation for
ground beef) or 46 °C (i.e., undercooked). Following cooking, each individual sample
was added to 100 mL peptone water (Becton, Dickinson and Company, Franklin Lakes,
NJ) with thorough mashing. The rinsate of each sample was 10-fold serially diluted in 1×
PBS, and each dilution (100 µL) was plated on LB agar supplemented with 100 µg/mL
ampicillin and incubated at 37°C overnight. Only fluorescent green colonies visualized
under UV light were enumerated.
For each spinach sample, three spinach leaves of similar size (average surface
area ~9 cm2) were selected and placed into a sterile container. All samples (n =
13/treatment) were inoculated with 100 µL mixture of E. coli O157:H7 at a concentration
of 108 CFU/mL by drop application. The phage treated group then received phage
treatment at an MOI of 1 by drop application, whereas the control group did not receive
any phage application. Samples were incubated at room temperature. The concentrations
of E. coli O157:H7 were determined at 24 h, 48 h, and 72 h post-treatment.
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Individual Swiss cheese samples (average surface area ~16 cm2, n = 10/treatment)
were inoculated with 100 µL of E. coli O157:H7 at a concentration of 108 CFU/mL by
drop application. The phage treated group received phage treatment at an MOI of 1 by
drop application, while the control group did not receive any phage application. Samples
were incubated at room temperature for 24 h and E. coli O157:H7 in individual samples
were enumerated.

2.3.5

Isolation of Phage Resistant E. coli O157:H7 Mutants

To isolate phage resistant E. coli O157:H7 mutants, E. coli O157:H7 strains 309
(non- GFP labeled) and 502 were infected with the 16 E. coli O157:H7 phages by spot
inoculation onto an overlay containing one of the two bacteria. After 18 h of coincubation, three single colonies, which were designated as 309-PR (phage-resistant) 1,
309-PR4 and 502-PR5, were isolated from FFH1-, FFH4- (vB_EcoM_FFH4) and FFH5(vB_EcoS_FFH5) lysed clear zones. The three colonies were purified, confirmed by PCR
(stx1, stx2 and eae, primers are listed in Table 1) and biochemical assay (API 20E,
BioMerieux Vitch, Inc., Hazelwood, MO) as E. coli O157:H7 and confirmed as phage
resistant by standard plaque assay.

2.3.6

Phage Adsorption in Phage Resistant E. coli O157:H7 Mutants

Bacterial cultures were grown to log-phase and then infected with corresponding
phages at an MOI of 0.1. Samples were taken in duplicate at 5 and 10 min post-infection
and centrifuged immediately at 10,000 × g for 10 s to separate unattached phage particles
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from bacteria. Titers of unattached phage in the supernatant were determined using
standard plaque assay. The experiments were independently conducted in triplicate.

2.3.7

In Vitro Stability of Phage Resistance

Phage resistant E. coli O157:H7 strains were subcultured in vitro in LB broth
every 12 h for 8 passages. The efficiency of plating (EOP) was determined for each
subculture by dividing the phage titer of the subculture by the phage titer of the phage
susceptible E. coli O157:H7 culture.

2.3.8

Fitness of Phage Resistant E. coli O157:H7 Mutants

To determine any potential fitness costs associated with phage resistance
development, growth kinetics and ability to adhere to mammalian intestinal cells were
measured in the phage resistant E. coli O157:H7 strains 309-PR1, 309-PR4, and 502-PR5.
To measure bacterial growth kinetics, log-phase cultures of phage susceptible and phage
resistant E. coli O157:H7 strains with identical OD600 values were inoculated at a ratio
of 1:100 to either fresh LB broth medium or autoclaved 10% bovine fecal suspension in
1× PBS. Cultures were sampled in triplicate at the starting time point and every hour for
9 h, and bacteria were enumerated on sorbitol MacConkey agar. Bacterial generation
times during log-phase and plateau concentrations during stationary phase were
determined from growth curves of best fit.
Adhesion experiments were conducted as described previously (Carlson et al.,
2009) with some modifications. Briefly, confluent Caco-2 monolayers were formed in 6well tissue culture plates (Corning Inc., Corning, NY) using Dulbecco's modified Eagle's
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medium (Invitrogen, Grand Island, NY) containing 20% heat-inactivated fetal bovine
serum (Atlanta Biologicals, Norcross, GA). Confluent Caco-2 monolayers were
inoculated with log-phase phage resistant and phage susceptible bacterial cultures at an
MOI of 50 and incubated at 37°C for 3 h. After infection, unattached bacteria were
removed by washing the monolayer three times with 1× PBS. The monolayer was treated
with 0.25% trypsin and attached bacteria were enumerated on sorbitol MacConkey agar.
The adhesion assay of each isolate was conducted independently in duplicate wells four
times. Adhesion percentage was calculated as the concentration of recovered E. coli
O157:H7 (CFU) compared with that of the inoculum.

2.3.9

Statistical Analysis

Statistical analysis was performed with GraphPad Prism (version 5.0) software
(GraphPad Software, San Diego, CA). Paired t-tests were used to determine if phage
treatment significantly reduced the population of viable E. coli O157:H7 on contaminated
ground beef and cheese at room temperature and refrigerated temperature. One-way
ANOVA and Tukey- Kramer multiple comparisons tests were used for undercooked meat
samples and Caco-2 cell adhesion data. Two-way ANOVA was used for spinach samples
and to compare the percentages of unabsorbed phages in adsorption assays. Treatments
were considered statistically different at P < 0.05. A lack-of-fit test was used to compare
growth curves between phage susceptible and phage resistant strains. Linear regression
was used to evaluate in vitro stability of phage resistance by examining any trends (i.e.,
decrease or increase in EOP) over 8 passages.
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2.4

Results

2.4.1 Phage Characterization
The three phages had similar lytic cycles, which were completed within 60 min.
With each phage, attachment was observed within 1 min and cycle started immediately.
The eclipse periods for FFH1, FFH2, and FFH3 were approximately 10 min, 25 min and
20 min and the latent periods were 33 min, 35 min, and 28 min, respectively. The burst
sizes of FFH1, FFH2, and FFH3 were 30.9, 18.6 and 524.8 PFU/cell (Figure 1).
Transmission electron microscopy revealed the morphology of the 3 coliphages
and showed that they belonged to 2 distinct families. The FFH1, FFH2, and FFH3 phages
were all tailed phages with icosahedral heads. Phage FFH2 was a member of the
Myoviridae family with a larger head and a contractile tail consisting of a baseplate and
spikes. Phages FFH1 and FFH3, as members of the Siphoviridae family, had longer but
noncontractile and flexible tails (Figure 2).

2.4.2

Phage Treatment of E. coli O157:H7 Contaminated Food Products

Concentrations of E. coli O157:H7 in phage treated ground beef were 1.97 ± 0.24
log10 CFU/mL less than those in untreated ground beef when samples were stored at
room temperature for 24 h and 0.48 ± 0.18 log10 CFU/mL less when stored under
refrigeration (Figure 3A and 3B; P < 0.05). When contaminated beef samples were
undercooked (i.e. internal temperature of 46°C), concentrations of E. coli O157:H7 in
phage treated ground beef were 0.56 ± 0.38 log10 CFU/mL less than those found in
untreated, undercooked ground beef (P < 0.05, Figure 3C). There was no significant
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difference in E. coli O157:H7 concentrations between phage treated and non-treated
groups when contaminated beef was cooked to an internal temperature of 63°C (Figure
3C).
Application of the phage cocktail reduced (P < 0.001) the concentration of viable
E. coli O157:H7 on spinach surfaces. Concentrations of E. coli O157:H7 on phagetreated spinach were 3.28 ± 0.74 log10 CFU/mL, 2.88 ± 0.74 log10 CFU/mL and 2.77 ±
0.74 log10 CFU/mL less than E. coli O157:H7 concentrations on untreated spinach after
storage at room temperature for 24 h, 48 h and 72 h, respectively (Figure 4). The effect of
phage treatment on E. coli O157:H7 reduction was consistent over time.
There were no significant differences between the concentrations of recovered E.
coli O157:H7 in phage-treated cheese versus untreated cheese. After 24 h at room
temperature, phage-treated cheese had concentrations of 4.15 log10 CFU/mL rinsate
compared with 4.23 log10 CFU/mL rinsate in untreated cheese.

2.4.3

Kinetics of Phage Infection of Phage Resistant Mutants

Compared with FFH1 infection of phage-susceptible E. coli O157:H7 strain 309
(Figure 1A), which had an eclipse period of 10 min, a latent period of 33 min and a burst
size of 30.9 PFU/cell, no phage proliferation was observed during the infection of FFH1
to phage-resistant strain 309-PR1 (Figure 5A) and, therefore, kinetic indices could not be
calculated. Phage FFH1 titer was observed to slightly decrease over the 1.5 h of sampling.
Phage FFH4 infection of the phage-susceptible E. coli O157:H7 strain 309
(Figure 5B) produced an eclipse period of approximately 30 min, a latent period of 43
min and a burst size of 95.9 PFU/cell. Infection of the phage-resistant strain 309-PR4
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(Figure 5C) produced similar eclipse and latent periods of 30 min and 43 min,
respectively, and a burst size of 43.65 CFU/mL, indicating the 309-PR4 was not
completely resistant to FFH4.
Phage FFH5 infection of the phage-susceptible E. coli O157:H7 strain 502
(Figure 5D) produced an eclipse period of 30 min, a latent period of 50 min and a burst
size of 57.54 PFU/cell. However, similar to the infection of FFH1 to 309-PR1, no phage
proliferation was observed during FFH5 infection of phage-resistant strain 502-PR5
(Figure 5E).
Each phage-resistant E. coli O157:H7 strain was also tested for cross-resistance to
other E. coli O157:H7 phages in our library. In isolate 309-PR1, resistance to FFH1
conferred resistance to two other phages (FFH6 and FFH7). In isolate 309-PR4,
resistance to FFH4 conferred resistance to four other phages (FFH2, FFH3, FFH7 and
FFH8). Similarly, resistance to FFH5 in isolate 502-PR5 conferred resistance to three
other phages (FFH9, FFH10 and FFH11).

2.4.4

Adsorption of Phage to Phage Resistant E. coli O157:H7 Mutants

The titer of adsorbed phages was represented as the initial phage inoculum minus
the recovered phage titer in supernatant. Adsorption of FFH1 to phage resistant E. coli
O157:H7 strain 309-PR1 did not differ compared with FFH1 adsorption to the susceptible
parent strain 309 (P = 0.25, Figure 6A). At 5 min post-infection, 74.11% of the initial
FFH1 inoculum adsorbed in 309-PR1 culture versus 79.33% in 309 culture. At 10 min
post-infection, 84.01% of the initial FFH1 inoculum adsorbed in 309-PR1 culture versus
91.00% in 309 culture.
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Adsorption of FFH4 to phage-resistant E. coli O157:H7 strain 309-PR4 was
significantly less compared with FFH4 adsorption to the susceptible parent strain 309 (P
< 0.01, Figure 6B). At 5 min post-infection, 31.86% of the initial FFH4 inoculum
adsorbed in 309-PR4 culture versus 84.38% in 309 culture. At 10 min post-infection,
41.10% of the initial FFH4 inoculum adsorbed in 309-PR4 culture versus 84.20% in 309
culture.
Similarly, adsorption of FFH5 to phage resistant E. coli O157:H7 strain 502-PR5
was significantly lower than FFH5 adsorption to the phage susceptible parent strain 502
(P < 0.01, Figure 6C). At 5 min post-infection, 8.35% of the initial FFH5 inoculum
adsorbed in 502-PR5 culture vs. 65.41% in 502 culture. After 10 min post-infection,
35.32% of the initial FFH5 inoculum adsorbed in 502-PR5 culture versus 89.65% in 502
culture.

2.4.5

In Vitro Stability of Phage Resistance

The EOP remained constant throughout the sub-culture period in phage resistant
E. coli O157:H7 strains 309-PR1, 309-PR4 and 502-PR5, indicating that phage resistance
was stable in vitro even though phage was withdrawn. While the EOP in the sub-cultures
of 309-PR1 and 502- PR5 remained < 1.27 × 10-8 and < 1.54 × 10-8, respectively, the
EOP in the sub-cultures of 309-PR4 remained as 0.10 ± 0.04.

2.4.6

Fitness of Phage Resistant E. coli O157:H7 Isolates

LB broth was used as a common laboratory growth medium for E. coli and 10%
bovine fecal suspension in 1× PBS was used to mimic a nutrient-limited environment. No
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growth differences were observed among phage susceptible E. coli O157:H7 strain 309
and its two phage-resistant strains (E. coli O157:H7 strains 309-PR1 and 309-PR4) in
doubling time or plateau concentrations during incubation in either LB broth (P = 0.5261,
Figure 7A) or 10% bovine fecal suspension (P = 0.1007, Figure 7B). Similarly, no
growth differences were observed between phage-susceptible E. coli O157:H7 strain 502
and its phage-resistant E. coli O157:H7 strain 502-PR5 in either LB broth (P = 0.2065,
Figure 7C) or 10% bovine fecal suspension (P = 0.1243, Figure 7D).
In terms of bacterial adhesion ability to Caco-2 human intestinal epithelial cells,
all of the tested E. coli O157:H7 strains had low recovered adhesion percentages. The E.
coli O157:H7 strains 309, 309-PR1 and 309-PR4 had recovered adhesion percentages of
2.20 ± 0.49%, 2.06 ± 0.42% and 2.13 ± 0.63%, respectively, and no statistical differences
were observed (P = 0.9833, Figure 8A). The E. coli O157:H7 strains 502 and 502-PR5
had recovered adhesion percentages of 0.92 ± 0.41% and 1.12 ± 0.67%, and no statistical
differences were observed (P = 0.8096, Figure 8B).
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2.5

Discussion

Interest in using bacteriophages as antibacterial interventions has grown due to
the emergence of antibiotic resistant bacteria. The potential of phages in limiting bacterial
infections or contamination has been shown previously (Sharma et al., 2009; Wall et al.,
2010; Loc-Carrillo and Abedon, 2011; Viazis et al., 2011; Hudson et al., 2013); however,
phages are comparatively understudied, which makes it difficult to predict where and
when phage therapy can be most effective and appropriate. In this study, we isolated 16 E.
coli O157:H7 phages from wastewater treatment facilities. Three phages (i.e., FFH1,
FFH2, and FFH3) were chosen from this collection based on their ability to lyse the
greatest number of individual E. coli O157:H7 strains. Here we determined the
antibacterial efficacy of selected phages in various food products, as well as characterized
phage resistance in E. coli O157:H7 strains in order to both gain a better understanding of
some of the basic biological characteristics of wild-type E. coli O157:H7 phages and to
identify phages that could more effectively limit contamination in different food matrices.
Many foods can be easily contaminated during processing, storage and
transportation. Whereas E. coli O157:H7 infections traditionally have been associated
with ground beef, outbreaks in recent years have also been linked to contaminated
produce and other ready-to-eat products (Nyachuba 2010). Our study, as well as those of
others (Leverentz et al., 2003; O’Flynn et al., 2004), has demonstrated the effectiveness
of phage therapy in post-harvest control of foodborne bacterial pathogens in meat and
fresh produce. The results of our study, perhaps for the first time, indicated that applying
phage treatment to contaminated ground beef can effectively reduce E. coli O157:H7
populations in improperly-cooked (i.e., undercooked) meat balls. This evidence provides
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a possible approach to limit outbreaks associated with improperly prepared beef products.
Likewise, the phage cocktail used in our study showed promising results in reducing E.
coli O157:H7 concentration in fresh spinach at room temperature, which was consistent
with another recent report (Abuladze et al., 2008). These observations may contribute to
practical biocontrols during post-harvest processing and transport of fresh spinach,
especially in the cases where normal refrigeration temperatures inadvertently increase, as
in the case with ‘hot trucks’. Our phages, however, were not effective in reducing E. coli
O157:H7 contamination in cheese. Leverentz et al. (2003) reported that levels of L.
monocytogenes-specific phages declined rapidly in fresh-cut apple slices (pH = 4.2), but
not in honeydew melon slices (pH = 5.8). However, the pH of the Swiss cheese used in
our study (i.e., pH = 5.68 to 6.62) was significantly less acidic than that of apples and
was similar to the pH of spinach (i.e., pH = 5.5 to 6.8). Therefore, a low pH seems not to
be the major reason preventing phage function in Swiss cheese. The cheese industry takes
several measures to control phage infection from interfering with the fermentation
process during manufacturing (Emond and Moineau, 2007) and the bacteriophage
inhibitory media left on the cheese may be a threat to phages (Samson and Moineau,
2013). Further studies are required to find the critical points in cheese processing where
phage treatment may be more effective and appropriate.
Phages are obligate parasites that depend on host machinery for replication. As
expected, our phage cocktail consistently performed better at higher temperature (i.e.,
20°C) rather than lower temperature (i.e., 4°C) because 20°C is closer to the optimum
temperature for E. coli O157:H7 (i.e., 37°C). It should be noted, however, that a previous
study using the ECP-100 phage cocktail to treat E. coli O157:H7-contaminated
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cantaloupes indicated that ECP-100 was more effective at low temperature (i.e., 4 °C)
than high temperature (i.e., 20°C) (Sharma et al., 2009). These results may be due to the
different physiological types of coliphages. Therefore, the three phages in our cocktail
may also belong to the high temperature (HT) or mid-temperature (MT) class of phages
which lyse bacteria more effectively at or above 15°C (Seeley et al., 1980).
Previous research showed that the efficacy of phages in reduction of E. coli
appeared to be correlated with the phage concentration used: a greater phage-to-bacteria
ratio resulted in a larger reduction of viable E. coli counts in all foods (Abuladze et al.,
2008; Goode et al., 2003). The bacterial concentration with which we challenged the
foods in our study was much greater than those commonly reported in outbreak
associated foods. The greater inoculation rate was used to avoid situations where phage
treatment reduced bacterial concentrations to levels under the limits of detection (102 to
103 CFU/mL depending on the sample), which obscures results. Therefore, under more
realistic conditions, phage treatment may be more effective than shown here. This may be
true, however, only within a certain range because phage association with host bacteria is
governed by second order kinetics. Therefore, if contamination rates are extremely low,
very high concentrations of phages may be needed to eliminate the target bacteria.
The development of resistance in bacteria is an unintended, however, unavoidable
phenomenon in many anti-bacterial applications. Phage therapy is no exception and the
emergence of phage-resistant bacteria is considered one of the obstacles that may limit
phage therapy from being widely applied (Sulakvelidze et al., 2001; Tanji et al., 2004).
According to previous studies, phage-resistant mutants were frequently detected within
hours to days in bacteria-phage coincubations in liquid media, especially when a single
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phage was used (Bohannan and Lenski, 2000; Mizoguchi et al., 2003; Tanji et al., 2004).
Our study showed similar results with all three phage-resistant E. coli O157:H7 mutants
being isolated after 18 h of coincubation on LB agar. The mechanisms of phage
resistance can be grouped into four major categories: adsorption prevention, prevention
of phage DNA entry, degradation of phage nucleic acid, and abortive infection systems
(Labrie et al., 2010). Among all, adsorption prevention is most commonly reported in
phage resistance E. coli in previous studies. Resistance to T2, T4, T7 and several E. coli
O157:H7-specific phages in E. coli has been associated with alteration or deletion of
phage adsorption receptors in bacterial cell surface structures, such as lipopolysaccharide
(LPS), OmpA, OmpC and OmpF (Bohannan et al., 2000; Morita et al., 2002; Tanji et al.,
2004). In addition, adsorption prevention in E. coli O157:H7 was also observed through
secretion of extracellular matrix (Mizoguchi et al., 2003). All three phage resistant E. coli
O157:H7 strains examined in this study had similar colony morphology compared with
their phage-susceptible parent strains. Based on phage adsorption assays, we determined
that the development of phage resistance in E. coli O157:H7 strains 309-PR4 and 502PR5 were, at least in part, due to phage adsorption prevention. Further analysis of LPS
and outer membrane protein profiles in both phage susceptible and phage resistant strains
may help identify phage receptors and determine how the alteration or deletion of phage
receptors contributed to phage resistance. The adsorption of phage to strain 309-PR1, on
the other hand, was not altered. However, no phage amplification was observed in singlestep growth curves, indicating phage resistance in 309-PR1 was due to mechanisms other
than adsorption prevention. More studies are needed to further determine the exact
mechanism of phage resistance in 309- PR1.
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A previous study (Scott et al., 2007) reported a reversion from phage resistance to
phage susceptibility in Campylobacter jejuni when the bacteria were inoculated into
chickens in the absence of phages. Similar reversions to phage susceptibility were also
observed in phage resistant E. coli O157:H7 mutants in vitro when they were passaged
through 50 generations (O’Flynn et al., 2004). However, we did not observe any
reversion to phage susceptibility in any of our phage resistant E. coli O157:H7 strains
during 8 sub-culture passages (equal to more than 250 generations). Other studies
(Quiberoni et al., 1999; Binetti et al., 2007) showed that the stability of phage resistance
could vary greatly among mutants with some mutants remaining phage resistant
throughout the test period and other mutants reverting within the first few sub-cultures.
The particular mechanisms of phage resistance and the genetic background of bacteria are
probably key factors that determine the stability of phage resistance.
Fitness cost was another phenomenon frequently associated with the development
of phage resistance. Bacterial cell surface structures that serve as receptors of phage
adsorption are often involved in other various aspects of bacterial physiology. The outer
membrane proteins, such as OmpA, OmpC and OmpF, function both as structural
proteins to maintain the outer membrane for the survival of bacteria in harsh
environments (Sonntag et al., 1978) and as porins for passive diffusion of nutrients,
toxins, and waste (Koebnik et al., 2000). In pathogenic bacteria, some cell surface
structures function as virulence factors that facilitate bacterial colonization and confer
serum resistance (Weiser and Gotschlich, 1991; Cornick et al., 2002). Therefore, phage
resistant mutants could be out-competed during the absence of phage due to a fitness cost.
However, unlike other reports showing that phage resistant mutants had decreased growth
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or attenuated colonization and invasion ability (Scott et al., 2007; Gómez and Buckling,
2011), no fitness cost in terms of growth kinetics or ability to adhere to mammalian
intestinal cells was observed in our phage resistant E. coli O157:H7 strains. Previous
studies (Bohannan and Lenski, 2000; Lopez-Pascua and Buckling, 2008) indicated that
environment could affect the cost of phage resistance. Phage resistance in bacteria
growing in environments with lower productivity tends to have a more apparent fitness
cost. It is possible that the cost of resistance in our mutants was not enough to cause any
growth or adhesion difference under laboratory settings. However, the environments
where phage treatments might be applied, such as animal intestinal tract, animal carcass
and food surface, are much more limited in nutrients while containing very complex
microbial communities. In this situation, a relatively low fitness cost may be enough to
cause the phage-resistant mutants to be out-competed when no phage selection pressure is
presented.
The ability of phage to evolve and potentially overcome phage resistance in
bacteria is commonly considered a major advantage that distinguishes phage therapy
from the use of antibiotics. Corresponding to the alteration of phage receptors in bacteria,
some phages, such as T7, evolved with host-range mutations that lead to infections of
both phage-resistant and phage- susceptible bacteria (Lenski and Levin, 1985). A similar
phenomenon was observed during the coincubation of FFH5 with phage resistant strain
502-PR5 in this study (data not shown), where a new phage was detected after 5 h of coincubation and confirmed to be lytic to both phage resistant strain 502-PR5 and phage
susceptible parent strain 502. Further genome analysis will be used to determine if the
new phage is a descendent of FFH5 and, if so, to determine the cause of the phenotype.
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One strategy that has been shown to be effective in mitigating phage resistance is
the use of a cocktail of multiple distinct phages. Compared with the use of a single phage,
the use of a phage cocktail could delay the development of phage resistance (Tanji et al.,
2004) due to low probability of a bacterium simultaneously developing multiple resistant
mechanisms or alterations in multiple phage receptors. However, in our situation,
resistance to the original test phage (i.e., FFH1, FFH4 or FFH5) conferred crossresistance to at least two other phages in our library. It should be noted, however, that
there is little clonal variation among E. coli O157:H7 strains and cross-resistance may be
much less in other bacterial strains. Nevertheless, it would be prudent to include several
phages with distinct genetic backgrounds to optimize phage cocktails in reducing the
emergence of phage resistance within a treatment period.
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2.6

Summary and Conclusions

Phage-based technologies have great potential as biocontrol agents in limiting both
disease transmission and contamination in food animal production. Here we
demonstrated that a rationally designed cocktail of phages chosen based on in vitro
kinetics, killing efficiencies and host range, significantly reduced E. coli O157:H7
contamination in different food matrices. By examining the efficacy of the treatment at
different temperatures, we hoped to better predict when and where phage-based
technologies can be applied most appropriately and effectively. Our results indicate,
however, that the development of resistance could interfere with the long-term efficacy of
phage-based therapeutics in manners similar to other antibacterial treatments such as
antibiotics. Therefore, prior to the widespread use of phages, it would be prudent to focus
research on better understanding how this resistance develops in order to develop
strategies that overcome or mitigate its effects.
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2.7

Note

Yanying Pan contributed to the study of evaluating the efficacy of phage treatments
to reduce E. coli O157:H7 contamination in foods and the results were also included in
her Master’s thesis.
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Figure 1. Growth kinetics of E. coli O157:H7 phages. Single-step growth curves of
FFH1 (A), FFH2 (B), and FFH3 (C). PFU = plaque forming units, E = eclipse period, L =
latent period and B = burst size.
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Figure 2. Transmission electron microscopy images of E. coli O157:H7 phages. FFH1
(A) and FFH3 (C), members of the Siphoviridae family, have small heads and long, noncontractile tails. FFH2 (B), a member of the Myoviridae family, has a large head and a
short, contractile tail. Magnification = 92,000×. Bars = 0.2 µm.
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Figure 3. Reduction of E. coli O157:H7 contamination in phage treated ground beef at
room temperature (A), under refrigeration (B), and when undercooked (C). Bars indicate
means within treatments. * = statistical differences (P <0.05) in mean bacterial
concentrations between treatment groups and within temperatures.
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Figure 4. Reduction of E. coli O157:H7 contamination in phage treated spinach. * =
statistical differences (P <0.05) in mean bacterial concentrations between treatment
groups and within time points.
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Figure 5. Phage growth kinetics in phage susceptible and phage resistant E. coli O157:H7.
Single-step growth curves of FFH1 infection in the phage resistant E. coli O157:H7 strain
309-PR1 (A), FFH4 infection in phage susceptible parent E. coli O157:H7 strain 309 (B)
and its phage resistant strain 309-PR4 (C), FFH5 infection in the phage susceptible parent
E. coli O157:H7 strain 502 (D) and its resistant strain 502-PR5 (E). PFU = plaque
forming units, E = eclipse period, L = latent period and B = burst size.
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Figure 6. Phage adhesion in phage susceptible and phage resistant E. coli O157:H7. The
percentages of adsorbed phage in (A) FFH1 infection of phage susceptible (309) and
phage resistant (309-PR1) E. coli O157:H7, (B) FFH4 infection of phage susceptible
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Figure 7. Growth characteristics of phage susceptible versus phage resistant E. coli
O157:H7. Bacterial growth curves of phage susceptible E. coli O157:H7 strain 309 and
phage resistant strains 309-PR1 and 309-PR4 in (A) Luria Bertani (LB) broth and (B)
10% bovine fecal suspension. Bacterial growth curves of phage susceptible E. coli
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71

Recovered adhesion
percentage, %

A

4
3
2
1
0
309

309-PR1
Bacterial strains

309-PR4

B
Recovered adhesion
percentage, %

4
3
2
1
0
502

502-PR5
Bacterial strains

Figure 8. Adhesion of phage susceptible and phage resistant E. coli O157:H7. Recovered
adhesion percentages of phage susceptible (309) and phage resistant (309-PR1 and 309PR4) E. coli O157:H7 309 strains (A) and phage susceptible (502) and phage resistant
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Table 1. Primers used in this study
Primer

DNA Sequence (5’ to 3’)

Product size (bp)

Stx1-F

TAG TGG AAC CTC ACT GAC GC

386

Stx1-R

TAT TGT GCG TAA TCC CAC GG

Stx2-F

GAC TAT CTT CAT TCA CGG CGC

Stx2-R

GCC GGG TTC GTT AAT ACG GC

Eae-F

GCA TTT GGT CAG GTC GGA GC

Eae-R

ATC GAA GCC ATT TGC TGG GC

536

270

73
List of References
Abuladze, T., M. Li, M. Y. Menetrez, T. Dean, A. Senecal, and A. Sulakvelidze. 2008.
Bacteriophages reduce experimental contamination of hard surfaces, tomato,
spinach, broccoli and ground beef by Escherichia coli. Appl. Environ. Microbiol.
74:6230-6238.
Binetti, A. G., N. B. Bailo, and J. A. Reinheimer. 2007. Spontaneous phage-resistant
mutants of Streptococcus thermophilus: isolation and technological characteristics.
Int. Dairy J. 17:343-349.
Bohannan, B. J. M., and R. E. Lenski. 2000. Linking genetic change to community
evolution: insights from studies of bacteria and bacteriophage. Ecol. Lett. 3:362377.
Carlson, B. A., K. K. Nightingale, G. L. Mason, J. R. Ruby, W. T. Choat, G. H.
Loneragan, G. C. Smith, J. N. Sofos, and K. E. Belk. 2009. Escherichia coli
O157:H7 strains that persist in feedlot cattle are genetically related and
demonstrate an enhanced ability to adhere to intestinal epithelial cells. Appl.
Environ. Microbiol. 75:5927-5937.
Cornick, N. A., S. L. Booher, and H. W. Moon. 2002. Intimin facilitates colonizaton by
Escherichia coli O157:H7 in adult ruminants. Infect. Immun. 70:2704-2707.
Emond, E., and S. Moineau. 2007. Bacteriophages and food fermentations. In: McGrath,
S., and D. Sinderen, editors. Bacteriophage: genetics and molecular biology.
Caister Academic Press, Norwich, United Kindom. p. 93-124.
Ellis, E. L., and M. Delbruck. 1939. The growth of bacteriophage. J. Gen. Physiol.
22:365-384.

74
Gómez, P., and A. Buckling. 2011. Bacteria-phage antagonistic coevolution in soil.
Science.332: 106-109.
Goode, D., V. M. Allen, and P. A. Barrow. 2003. Reduction of experimental Salmonella
and Campylobacter contamination of chicken skin by application of lytic
bacteriophages. App. Env. Micro. 69:5032-5036.
Grauke, L. J., I. T. Kudva, J. W. Yoon, C. W. Hunt, C. J. Williams, and C. J. Hovde.
2002. Gastrointestinal tract location of Escherichia coli O157:H7 in ruminants.
Appl. Environ. Microbiol. 68:2269-2277.
Hudson, J. A., C. Billington, A. J. Cornelius, T. Wilson, S. L. W. On, and A. Premaratne.
2013. Use of a bacteriophage to inactivate Escherichia coli O157:H7 on beef.
Food. Microbiol. 36:14-21.
Koebnik, R., K. P. Locher, and P. Van Gelder. 2000. Structure and function of bacterial
outer membrane proteins: barrels in a nutshell. Mol. Microbiol. 37:239-253.
Labrie, S. J., J. E. Samson, and S. Moineau. 2010. Bacteriophage resistance mechanisms.
Nat. Rev. Microbiol. 8:317-327.
Lenski, R. E., and B. R. Levin. 1985. Constraints on the coevolution of bacteria and
virulent phage: a model, some experiments, and predictions for natural
communities. Am. Nat. 125:585-602.
Leverentz, B., W. S. Conway, M. J. Camp, W. J. Janisiewicz, T. Abuladze, M. Yang, R.
Saftner, and A. Sulakvelidze. 2003. Biochontrol of Listeria monocytogenes on
fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin. Appl.
Environ. Microbiol. 69:4519-4526.

75
Loc-Carrillo, C., and S. T. Abedon. 2011. Pros and cons of phage therapy. Bacteriophage
1:111- 114.
Lopez-Pascua, L. D. C., and A. Buckling. 2008. Increasing producitivity accelerates hostparasite coevolution. J. Evol. Biol. 21: 853-860.
McGee, P., L. Scott, J. J. Sheridan, B. Earley, and N. Leonard. 2004. Horizontal
transmission of Escherichia coli O157:H7 during cattle housing. J. Food. Prot.
67:2651-2656.
Mizoguchi, K., M. Morita, C. R. Fischer, M. Yoichi, Y. Tanji, and H. Unno. 2003.
Coevolution of Bacteriophge PP01 and Escherichia coli O157:H7 in continuous
culture. Appl. Environ. Microbiol. 69: 170-176.
Morita, M., Y. Tanji, K. Mizoguchi, T. Akitsu, N. Kijima, and H. Unno. 2002.
Chracterization of a virulent bacteriophage specific for Escherichia coli O157:H7
and analysis of its cellular receptor and two tail fiber genes. FEMS Microbiol.
Lett. 211:77-83.
Nyachuba, D. G. 2010. Foodborne illness: is it on the rise? Nutr. Rev. 68:257:269.
O'Flynn, G., R. P. Ross, G. F. Fitzgerald, and A. Coffey. 2004. Evaluation of a cocktail
of three bacteriophages for biocontrol of Escherichia coli O157:H7. Appl.
Environ. Microbiol. 70:3417-3424.
Quiberoni, A., J. A. Reinheimer, and V. B. Suarez. 1999. Performance of Lactobacillus
helveticus spontaneous phage-resistant mutants in hard cheese production. Int.
Dairy J. 8:941-949.

76
Rangel, J. M., P. H. Sparling, C. Crowe, P. M. Griffin, and D. L. Swerdlow. 2005.
Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002.
Emerg. Infect. Dis. 11:603-609.
Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory
Manual, Second Edition. Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY.
Samson, J. E., and S. Moineau. 2013. Bacteriophages in food fermentations:new frontiers
in a continuous arms race. Annu. Rev. Food Sci. Tech. 4:347-368.
Scallan, E., R. M. Hoekstra, F. J. Angulo, R. V. Tauxe, M. A. Widdowson, S. L. Roy, J.
L. Jones, and P. M. Griffin. 2011. Foodborne Illness Acquired in the United
States-major pathogens. Emerg. Infect. Dis. 17:1339-1340.
Scott, A. E., A. R. Timms, P. L. Connerton, C. L. Carrillo, K. A. Radzum, and I. F.
Connerton. 2007. Genome dynamics of Campylobacter jejuni in response to
bacteriophage predation. PLoS Pathog. 3:1142-1151.
Seeley, N. D., and S. B. Primrose. 1980. The Effect of Temperature on the Ecology of
Aquatic Bacteriophages. J. Gen. Virol. 46:87-95.
Sharma, M., J. R. Patel, W. S. Conway, S. Ferguson, and A. Sulakvelidze. 2009.
Effectiveness of bacteriophages in reducing Escherichia coli O157:H7 on freshcut cantaloupes and lettucet. J. Food Prot. 72:1481-1485. Sonntag, I., H. Schwarz,
Y. Hirota, and U. Henning. 1978. Cell envelope and shape of Escherichia coli:
multiple mutants missing the outer membrane lipoprotein and other major outer
membrane proteins. J. Bacteriol. 136:280-285

77
Sulakvelidze, A., Z. Alavidze, and J. G. Jr. Morris. 2001. Bacteriophage therapy.
Antimicrob. Agents Ch. 45:649-659.
Tanji, Y., T. Shimada, M. Yoichi, K. Miyanaga, K. Hori, and H. Unno. 2004. Toward
rational control of Escherichia coli O157:H7 by a phage cocktail. Appl Microbiol.
Biot. 64:270- 274.
Viazis, S., M. Akhtar, J. Feirtag, A. D. Brabban, and F. Diez-Gonzalez. 2011. Isolation
and characterization of lytic bacteriophages against enterohaemorrhagic
Escherichia coli. J. Appl. Microbiol. 110:1323-1331.
Wall, S. K., J. Zhang, M. H. Rostagno, and P. D. Ebner. 2010. Phage therapy to reduce
preprocessing Salmonella infections in market-weight swine. Appl. Environ.
Microbiol. 76:48-53.
Weiser, J. N., and E. C. Gotschlich. 1991. Outer membrane protein A (OmpA)
contributes to serum resistance and pathogenicity of Escherichia coli K-1. Infect.
Immun. 59:2252- 2258.

78

CHAPTER 3. COMPLETE GENOME SEQUENCES OF TWO ESCHERICHIA COLI
O157:H7 PHAGES EFFECTIVE IN LIMITING CONTAMINATION OF FOOD
PRODUCTS

3.1

Abstract

We previously demonstrated that application of bacteriophages significantly
reduced Escherichia coli O157:H7 contamination in spinach and ground beef. Here, we
present the genomic sequences of two bacteriophages, vB_EcoS_FFH_1, a T5-like phage,
and vB_EcoM_FFH_2, an rV5-like phage, used in those treatments.

3.2

Genome Annoucement

Escherichia coli O157:H7 is a shiga toxin-producing food-borne pathogen that
results in over 60,000 illnesses each year in the United States alone (Scallan et al., 2011).
We have employed bacteriophages to limit Salmonella transmission in swine (Wall et al.,
2010) and recently demonstrated that application of lytic bacteriophages to ground beef
and spinach significantly reduced E. coli O157:H7 contamination (Hong et al., 2014). We
selected two E. coli phages (vB_EcoS_FFH_1 [siphovirus] and vB_EcoM_FFH_2
[myovirus]) for genomic sequencing based on their broad spectrum and lytic capacity.
Phage DNA was purified from polyethylene glycol (PEG)-precipitated lysates and
sequenced via pyrosequencing (454; Eurofins MWG Operon, Huntsville, AL) and
sequences were assembled de novo using Newbler (version 2.6). Coding DNA sequences
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(CDSs) were predicted using Glimmer 3.0 (Delcher et al., 1999) and annotation was
performed using BLASTp for homology searching in the non-redundant protein
sequences database in GenBank (Benson et al., 2012). tRNA genes were predicted using
both tRNAscan-SE 1.21 (Schattner et al., 2005) and ARAGORN (Laslett and Canback,
2004). Terminal redundant ends (vB_EcoM_FFH_1) were identified using Tandem
Repeat Finder (Benson, 1999).
The genome of vB_EcoS_FFH_1 has a length of 108,483 bp and a G+C content
of 39.24%. Whole genome alignment revealed that vB_EcoS_FFH_1 showed 87%
homology to T5 (GenBank accession no. AY543070) and therefore was classified as a
T5-like phage. A total of 162 CDSs and 24 tRNA genes were predicted. Similar high
numbers of tRNA genes are found in T5. Of the CDSs, 54 matched proteins with known
functions, while 96 encoded previously identified hypothetical proteins. Twelve CDSs
did not match any proteins in the NCBI non-redundant protein database. We identified
putative Rz and Rz1 genes based on Summer et al. (Summer et al., 2007). Highly similar
sequences are also present in T5, but are not annotated in the three GenBank T5 complete
genomes and other available T5-like phage genomes. One section (79,918 to 84,241) of
the vB_EcoS_FFH_1 genome appeared largely absent from the three GenBank annotated
T5 genomes, but present in the bV_EcoS_AKFV33 genome (another T5-like phage).
Two putative tail fiber proteins and one hypothetical protein were identified in this
section.
The genome of vB_EcoM_FFH_2 has a length of 139,020 bp and a G+C content
of 43.61%. Whole genome alignment revealed that vB_EcoM_FFH_2 shared 93%
nucleotide homology to E. coli phage rV5 (GenBank accession no. DQ832317),
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indicating that vB_EcoM_FFH_2 is an rV5-like phage. A total of 220 CDSs and 6 tRNA
genes were predicted. Of the CDSs, 57 matched proteins with known functions, while
156 matched previously identified hypothetical proteins. Seven CDSs were not
homologous to any existing proteins in the NCBI non-redundant protein database.
Several complete genomes of rV5-like viruses are now available. The viruses share a
high number of proteins, but based on whole-genome comparisons, two rV5-like subgroups may exist, rV5 and Salmonella phage PVP-SE1 (Truncaite et al., 2012; Kropinski
et al., 2013; Kim et al., 2014). vB_EcoM_FFH_2 has significantly more sequence
similarity to rV5 (both of which were isolated using E. coli O157:H7), which would
make it a member of the rV5 sub-group.
The complete sequences of vB_EcoS_FFH_1 and vB_EcoM_FFH_2 were
deposited in GenBank under the accession numbers KJ190157 and KJ190158,
respectively.
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CHAPTER 4. TREATMENT OF SALMONELLA CONTAMINATED EGGS AND
PORK WITH A BROAD-SPECTRUM, SINGLE BACTERIOPHAGE:
ASSESSMENT OF EFFICACY AND RESISTANCE DEVELOPMENT

4.1

Abstract

Salmonella remains a leading cause of foodborne illness, with Salmonella
Typhimurium and Salmonella Enteritidis being two predominant serovars in both the US
and Europe. Numerous studies have focused on assessing the efficacy of using phagebased methods to eliminate or control Salmonella contamination in various food products.
Due to the narrow spectrum of phages, many of these studies used mixtures of several
distinct phages to expand the treatment spectrum, but also to prevent problems that may
arise due to the development of phage resistance. However, there is little practical
evidence to substantiate the need for “cocktails” that contain numerous unrelated phages.
In this study, we tested the ability of a single, well-characterized broad-spectrum
Salmonella phage, vB_SalS_SJ_2 (SJ2), to reduce Salmonella Typhimurium and
Salmonella Enteritidis in ground pork and eggs. Compared to untreated samples, phage
treatment significantly (P<0.05) reduced Salmonella Typhimurium by 1.65 log10
CFU/mL, 1.39 log10 CFU/mL, 0.29 log10 CFU/mL and 0.43 log10 CFU/mL in ground
pork and by 3.14 log10 CFU/mL, 0.49 log10 CFU/mL, 0.61 log10 CFU/mL and 0.51 log10
CFU/mL in liquid egg after treatment at room temperature for 24 h and 48 h and at
refrigeration for 24 h and 1 wk, respectively. Similarly, phage treatment significantly (P <

84
0.05) reduced Salmonella Enteritidis by 1.04 log10 CFU/mL and 1.30 log10 CFU/mL in
ground pork and by 0.93 log10 CFU/mL and 0.61 log10 CFU/mL in liquid egg after
treatment at room temperature for 24 h and 48 h, respectively. Under refrigeration,
significant reductions (P<0.05) of Salmonella Enteritidis were only seen in phage-treated
meat (0.25 log10 CFU/mL and 0.64 log10 CFU/mL reductions at 24 h and 1 wk,
respectively). No reductions of Salmonella Typhimurium or Salmonella Enteritidis were
observed under refrigerated conditions for 2 wk in either food product. The susceptibility
of Salmonella isolates to phage SJ2 was also tested after each phage treatments.
Significantly (P<0.05) higher percentages of phage resistant Salmonella Typhimurium
(92.50% vs. 0.56% of control) and Salmonella Enteritidis (50.83% vs. 0.56% of control)
isolates were observed in phage-treated liquid egg samples than non-treated samples after
incubation at room temperature for 48 h. Interestingly, such differences were not
observed between phage-treated and non-treated ground pork samples that were
incubated under the same conditions, indicating food matrix could influence the
emergence of phage resistance in foods. Taken together, this study demonstrated that a
single, broad-spectrum phage (SJ2) can effectively reduce Salmonella and the
development of phage resistance may be dependent on the targeted food matrix.
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4.2

Introduction

Salmonella is a ubiquitous foodborne pathogen that has been associated with
recalls of a wide variety of foods. Although multiple strategies have been employed to
prevent and eliminate Salmonella contamination at various points in the production and
processing chains, Salmonellosis remains a top foodborne illness in the US (Scallan et al.,
2011), indicating there is a need for more effective anti-Salmonella strategies. Among
many others, phage-based methods have shown potential to control Salmonella in various
food matrices and offer the unique advantages of targeting specific bacteria while being
natural and self-limiting. Previous studies have shown the efficacy of phages to reduce
Salmonella, mainly serovars Typhimurium and Enteritidis, in various food under
laboratory conditions, including chicken breast, shell and liquid eggs, lettuce, and juice
(Leverentz et al., 2001; Hungaro et al., 2013; Spricigo et al., 2013). The use of phages is
not limited to the control of Salmonella, as others have employed phages to target various
other pathogens including E. coli O157:H7 (Abuladze et al., 2008; Carter et al., 2012;
Hong et al., 2014), Campylobacter (Kittler et al., 2013), and Listeria (Leverentz et al.,
2003; Anany et al., 2011). Currently, there are commercially available phage-based
products for food processing in both the US and elsewhere. Some products have received
further approval as GRAS for use in ready-to-eat food or OMRI for use in organic
production.
The majority of the aforementioned studies used phage cocktails, or mixtures of
several distinct phages, largely in attempt to increase the host-spectrum as phages can be
highly specific for certain bacterial species and sub-species. Such high host specificity
can be problematic in reality where phages generally are applied before the exact bacteria
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in the foods or environment are known. Alternatively, using broad-spectrum phages
could also address the problem. Compared to the use of phage cocktail, however,
treatments based on single-phage can been more precisely defined and thus could more
easily receive regulatory approval (Carlton et al., 2005). A major concern, however, is the
development of resistance, which would theoretically be slower or absent if phage
treatments consist of several unrelated phages. To date, the efficacy of using a single,
broad-spectrum phage to reduce foodborne pathogens in foods has been far less studied
than the use of cocktails. In this study, we tested the potential of the well-characterized,
broad-spectrum Salmonella phage vB_SalS_SJ_2 (SJ2) to reduce Salmonella
Typhimurium and Salmonella Enteritidis in ground pork and liquid eggs. We also
measured the development of bacterial resistance to the phage to determine its impact on
efficacy.
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4.3

Materials And Methods

4.3.1 Bacteria and Bacteriophage
Salmonella Typhimurium γ4232 (nalidixic acid resistant) was previously isolated
from a diseased pig (Ebner and Mathew, 2000) and Salmonella Enteritidis was kindly
provided by Dr. Arun K. Bhunia (Purdue University, West Lafayette, IN). Phage SJ2 was
previously isolated from a wastewater treatment plant in Indiana using Salmonella
Typhimurium as a host (Wall et al., 2010). The phage has been well characterized both
genetically and kinetically. It is a siphorvirus with a genome size of 152,460 bp and
contains 197 predicted genes. The phage also showed the broadest spectrum among a
library of Salmonella phages, with high killing efficiency against Salmonella serovars
Typhimurium, Enteritidis, Indiana, and Kentucky (Zhang et al., 2015).

4.3.2

Phage Treatment of Salmonella Contaminated Food Products

Ground pork and shell eggs were purchased from local retail stores. All samples
were tested for Salmonella prior to any further phage testing. To test phage efficacy in
ground pork, ten samples were used for both control and phage treatment. Fifteen gram
samples were placed in a sterile stomacher bag (VWR International, Radnor,
Pennsylvania) and inoculated with 107 CFU of either Salmonella Typhimurium or
Salmonella Enteritidis in 100ul of Luria-Bertani (LB) broth, and massaged by hand
thoroughly to ensure even contamination throughout the sample. Phage treated samples
were then inoculated with 108 PFU of phage SJ2 suspended in 100 uL of phosphate
buffered saline (PBS), while untreated samples received a same amount of PBS only. All
samples were once again massaged by hand after inoculation and incubated under one of
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five conditions: room temperature for 24 h, room temperature for 48 h, 4 °C for 24 h,
4 °C for 1 wk, and 4 °C for 2 wk. After incubation, meat samples were resuspended in
100 mL of buffered peptone water (Becton, Dickinson and Company, Franklin Lakes,
NJ), the suspension was serially diluted and the concentration of Salmonella were
determined by plating on either XLT4 agar plates (Becton, Dickinson and Company,
Franklin Lakes, NJ) containing 50 ug/mL of nalidixic acid (Alfa Aesar, Ward Hill, MA)
for Salmonella Typhimurium or XLD agar plates (Becton, Dickinson and Company,
Franklin Lakes, NJ) for Salmonella Enteritidis, as XLT4 plates greatly inhibited the
growth of Salmonella Enteritidis strain used in this study (data not shown). Experiment
was repeated independently three times.
To test the efficacy of phage treatment in liquid egg, ten samples were used for
both control and phage treatment. Egg shells were wiped with 70% alcohol and air-dried
before breaking to avoid unintended contamination of Salmonella from outer surfaces.
Eggs were then mixed and homogenized at high speed. Liquid egg samples (15 mL)
were inoculated with 107 CFU of Salmonella Typhimurium or Salmonella Enteridis in
100 ul volume and vortexed to mix thoroughly. Phage treated samples were treated with
108 PFU of SJ2 in 100 ul of PBS and control samples received a same amount of PBS
only. Samples were once again vortexed after inoculation and incubated under one of
same five conditions previously described for pork experiments. After incubation,
Salmonella concentrations were quantified as previously described. Each experiment was
repeated independently three times.
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4.3.3

Phage Susceptibility of Salmonella After Phage Treatment

To test the development of phage resistance in the challenge Salmonella after
treatment with phage SJ2 under different conditions, 24 Salmonella isolates from each
phage treated sample and 12 Salmonella from each control samples were collected.
Isolates were picked from enumeration plates using sterilized toothpicks and were
resuspended in individual tubes containing 900 ul of PBS. Following a brief vortex, a 5
uL of each suspension was dropped onto an overlay containing a high concentration of
SJ2 and the plates were incubated at 37 °C overnight. Salmonella isolates that formed
complete bacterial lawns at dropped spots were considered resistant to phage SJ2.

4.3.4

Statistical Analysis

A random block design with replications was used to test the effect of phage SJ2
in reducing Salmonella contamination in both ground pork and liquid egg. Both the
concentration of Salmonella in foods and the percentage of phage resistant colonies were
analyzed using a mixed model analysis of variance (SAS 9.4) with the percentages of
phage resistant colonies being transformed into ranks.
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4.4
4.4.1

Results

Phage Treatment of Salmonella Contaminated Ground Pork

In Salmonella Typhimurium contaminated ground pork, samples that received
treatment of phage SJ2 had significantly (P<0.05) lower concentrations of Salmonella
Typhimurium than untreated samples by 1.65 Log10 CFU/mL (Fig 1A) and 1.39 Log10
CFU/mL (Fig 1B) after incubation at room temperature for 24 and 48 h, respectively.
While less effectively numerically, the concentrations of Salmonella Typhimurium in SJ2
treated ground pork were also significantly lower (P<0.05) than those in control samples
by 0.29 Log10 CFU/mL (Fig 1C) and 0.43 Log10 CFU/mL (Fig 1D) after incubation at
4 °C for 24 hr and 1 wk, respectively. However, the concentrations of Salmonella
Typhimurium in ground pork recovered after incubation at 4 °C for 2 wk were not
different between control and phage treated groups (Fig 1E).
Similarly, in Salmonella Enteritidis contaminated ground pork, samples that were
treated with SJ2 had significantly (P<0.05) lower concentrations of Salmonella
Enteritidis than untreated samples by 1.04 Log10 CFU/mL (Fig 2A) and 1.30 Log10
CFU/mL (Fig 2B) after incubation at room temperature for 24 or 48 h, respectively. The
reduction was again lower under refrigeration (4 °C), but still significant, with the
concentrations of Salmonella Enteritidis lower in SJ2-treated than in control samples by
0.25 Log10 CFU/mL (Fig 2C) and 0.64 Log10 CFU/mL (Fig 2D) after 24 and 48 h,
respectively. No difference was observed between control and phage treated samples in
the concentration of Salmonella Enteritidis after incubation at 4 °C for 2 wk (Fig 2E).
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4.4.2

Phage Treatment of Salmonella Contaminated Liquid Egg

In Salmonella Typhimurium contaminated liquid eggs, the concentration of
Salmonella Typhimurium in SJ2-treated samples was significantly (P<0.05) lower than
that in control samples by 3.14 Log10 CFU/mL (Fig 3A) and 0.49 Log10 CFU/mL (Fig 3B)
after incubation at room temperature for 24 h and 48h, respectively. Under refrigeration,
the concentrations of Salmonella Typhimurium in SJ2-treated samples were lower than
control samples by 0.61 Log10 CFU/mL (P<0.05, Fig 3C) and 0.51 Log10 CFU/mL
(P<0.05, Fig 3D) after incubation for 24 h and 1 wk, respectively. No concentration
difference was observed when samples were incubated at 4 °C for 2 wk (Fig 3E).
In Salmonella Enteritidis contaminated liquid egg, the concentrations of
Salmonella Enteritidis in SJ2-treated samples were significantly lower than that in control
samples by 0.93 Log10 CFU/mL (Fig 4A) and 0.62 Log10 CFU/mL (Fig 4B) after
incubation at room temperature for 24 h and 48 h, respectively. The concentrations of
Salmonella Enteritidis were not different between control and phage treated samples after
incubation at 4 °C for 24 h, 1 wk or 2 wk (Fig 4C-4E).

4.4.3

Development of Phage Resistant Salmonella

By using non-parametric analysis, it was observed that, at room temperature, the
percentage of phage resistant Salmonella Typhimurium in phage-treated liquid eggs was
numerically higher than that of untreated eggs after incubation for 24 h (untransformed
means of 14.44% vs. 0.56%, P=0.0794, Fig 5A) and significantly higher for 48 h
(untransformed means of 92.50% vs. 0.56%, P<0.05, Fig 5B). Similarly, at room
temperature, the percentage of phage resistant Salmonella Enteritidis in phage-treated
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liquid eggs was not significantly different from that of untreated eggs after incubation for
24 h (untransformed means of 3.75% vs. 1.11%, P=0.2036, Fig 5C) and significantly
higher for 48 h (untransformed means of 50.83% vs. 0.56%, P<0.05, Fig 5D). Such
differences were not observed between phage treated and non-treated ground meat
samples incubated at room temperature for 24 h or 48 h, in either Salmonella serovar (Fig
6A-D). Additionally, the percentages of phage resistant colonies were not different
between phage treated samples and controls at 4 °C for all incubation periods and
Salmonella seravars (data not shown).
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4.5

Discussion

Phage-based antibacterial methods have received much attention in recent years
due to their unique advantages as well as their ability to kill antibiotic resistant bacteria.
However, in practice, one of the distinct advantages of phages, the high target specificity,
may limit the use of phages for certain treatments (Loc-Carrillo and Abedon, 2011), such
as the applications in foods, where the exact species or strain is often not known. Several
groups have used phage cocktails (Leverentz et al., 2001; Leverentz et al., 2003; Hungaro
et al., 2013; Spricigo et al., 2013; Hong et al., 2014) and broad-spectrum phages (Carlton
et al., 2005; Guenther et al., 2009; Guenther et al., 2012) in attempt to increase the hostspectrum. While using phage cocktails can easily expand the target spectrum, it is not
without its own set of challenges (Chan et al., 2013). As has been reported previously,
phages in the cocktail can function synergistically or antagonistically (Hall et al., 2012),
therefore, in order to optimize the effect of a phage cocktail, phages must be carefully
selected and highly characterized to avoid deleterious interactions within the cocktail
itself. In addition, most published phage genomes contain very large un-annotated
sections, which complicates the comparison between unrelated phages. For example,
73.6% of the predicted genes in phage SJ2 genome (Zhang et al., 2015) do not match any
record with known functions in NCBI database. Similar published phage genomes
contain comparative percentages of unknown and un-annotated sequences (Kropinski et
al., 2013; Hong et al., 2014; Zhang et al., 2014). Additionally, large unknown sections
may include undesirable elements such as genes involved in lysogeny or virulence. This
likelihood, while quantitatively unknown, would increase with the number of phages
included in the cocktail. Thus, it may be safer and more time-efficient to use a single,
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very well characterized phage if challenges associated with resistance development are
easily overcome. Finally, with available phage products, each phage in the cocktail has
historically required individual regulatory approval, leading to additionally higher
development and production costs and time (Thiel, 2004).
While the balance of achieving relative broad-spectrum and maintaining
simplicity in the phage product may be found in the use of single broad-spectrum phage,
the efficacy of such application in foods is currently understudied. While nearly 2,500
Salmonella serovars have been documented, Salmonella Typhimurium and Salmonella
Enteritidis are the predominant serovars both in the US and Europe (Guenther et al., 2012)
and were therefore selected in this study. Foods of animal origins, such as meat, poultry
and eggs, are major vehicles of Salmonella. Particularly, Salmonella Enteritidis is a
predominant serovar in eggs. Ground meat and liquid egg, due to the nature of the
products as a mixture of meat or eggs from multiple sources, may have higher risk of
Salmonella contamination. The efficacy of using single, broad-spectrum anti-Salmonella
phage was tested under both refrigerated temperature to resemble conditions during food
storage and transportation and room temperature to mimic temperature-violation
situations. As expected, reductions of Salmonella were less effective under refrigeration.
The reduction in efficacy was seen in both Salmonella serovars as well as both food
matrixes tested. Similar results were also observed in our previous research focused on
reducing E. coli O157:H7 in ground beef, where a reduction of 0.48 log CFU/ml of E.
coli O157:H7 was observed at 4 °C after 24 h, while incubation at room temperature
reduced the concentration by 1.97 log CFU/mL (Hong et al., 2014). Phages are obligate
parasites of their host bacteria; therefore, the optimal growth temperature of the host
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bacterium is likely also the optimal temperature for the corresponding phage. Under
lower than optimal temperature, the penetration of phage genetic materials into host cells
is inhibited (Jończyk et al., 2011) leading to the lower lytic activity of the phages. While
a previous study indicated that phages were more effective under refrigeration (Sharma et
al., 2009), it should be noted that a higher MOI (MOI=100) was used in that experiment,
where phages could lyse or at least adhere to bacteria during the first few minutes of
treatment. Lower MOIs (i.e. MOI of 10 was used in this study), however, do not favor
lysis from without. Therefore, samples infected with lower concentrations of phages may
require a more optimum temperature to result in appreciable cell lysis.
A high concentration of Salmonella inoculum (approximately 106 CFU/gram in
ground pork and 106 CFU/mL in liquid egg) was used to prevent bacteria concentrations
from falling under detection levels (103 CFU/gram in meat and 10 CFU/mL in liquid egg)
after refrigeration and phage treatment. In reality, pathogens are usually present in lower
concentrations (i.e. <104 CFU/mL, Bigwood et al., 2009) leading to the use of higher
MOI, which will likely result in greater pathogen reductions as shown in a previous study
(Abuladze et al., 2008). Although, for bacteria at extreme lower concentrations, the
reduction becomes independent of MOI and a sufficiently high concentration of phage
will results in similar reduction regardless of the resulted MOIs (Bigwood et al., 2009).
One purpose of using phage cocktail is to mitigate the development of phage
resistance, as it is much less probable that the bacterial host would develop resistance
simultaneously to several distinct phages (Hong et al., 2014). Here we aimed to
determine how often and how soon targeted bacteria might become resistant to a single
phage within a food matrix. Interestingly, our results showed that the emergence of phage
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resistant bacteria varied between the two different food matrixes. Significantly higher
levels of phage resistant Salmonella isolates were detected in liquid egg samples, but not
in ground pork samples, after phage treatment at room temperature for two days. Similar
results were observed for both Salmonella Typhimurium and Salmonella Enteritidis,
indicating that food matrix may influence the development of phage resistant Salmonella
isolates. A previous study (Guenther et al., 2009) pointed out that the limited diffusion of
phages in different food matrices is an important factor to considerate during the
development of phage applications in foods. Phage diffusion is expected to be most
difficult in foods, such as meat, with large and uneven surface area. Although in this
experiment ground meat samples were hand massaged after phage inoculation, the
complex matrix of meat, such as the presence of fat, could prevent the contact between
phages and bacteria. In contrary, the diffusion of phages in liquid egg, while not as freely
as in the chocolate milk or mozzarella cheese brine tested in the aforementioned study, is
better than that in ground meat samples. Therefore, bacteria and phage in liquid egg are
more accessible to each other. The increase in phage-bacteria interactions could, by
probability, increase the likelihood of selecting phage resistant bacteria. Additionally,
other bacteria presented in the foods may also influence the development of phage
resistance. The reduction of Salmonella by phage provides surrounding bacteria an
opportunity to grow, which in turn results in growth competition with phage resistant
Salmonella strains. Due to the nature of foods, ground pork likely harbors a more diverse
microbiome than liquid eggs, which are often functionally sterile. Therefore, phage
resistance strains that emerge in ground pork may be subject to stronger growth
competition. High levels (10 out of 10 tested colonies) of phage resistant isolates were
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also recovered from egg yolk and chocolate milk after treatment with a single Salmonella
phage for 6 days at 15 °C (Guenther et al., 2012). The same study also showed that under
a high MOI setting where great reductions of bacteria resulted, the emergence of phage
resistant isolates might not compromise the initial phage efficacy, at least as observed in
chocolate milk. While not statistically significant, numerically higher percentages of
phage resistant Salmonella Typhimurium isolates were also detected in phage treated
liquid egg samples after one day at room temperature, suggesting development of phage
resistance may be rapid in certain foods. Additionally, the percentages of phage resistant
isolates were not different between phage treated and non-treated samples under
refrigerated conditions at any time point. This is understandable as low temperature likely
inhibited the physical activity of both the host bacteria as well as the phage.
Taken together, this study demonstrated the potential of using a single, broadspectrum phage, SJ2, in controlling Salmonella Typhimurium and Salmonella Enteritidis
contamination in ground pork and liquid egg. In future studies, the efficiency of SJ2
should also be tested at lower bacterial conditions, which more closely resemble a
production-like setting. While the significantly higher levels of phage resistant
Salmonella isolates in phage-treated liquid egg samples at room temperature indicate that
liquid egg might not be an ideal food matrix for phage treatment, it would still be of
interest to see whether similar high percentages of phage resistance occur at high MOI
setting and quantify the potential impact of resistance on subsequent phage applications.
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Figure 1: Reduction of Salmonella Typhimurium contamination in phage treated ground
pork at room temperature after 24 h (A) and 48 h (B), and at 4 °C after 24 h (C), 1 wk (D)
and 2 wk (E). Bars indicate means within treatments. * = statistical differences (P <0.05)
in mean bacterial concentrations between treatment groups.
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indicate means within treatments. * = statistical differences (P <0.05) in mean bacterial
concentrations between treatment groups.
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between treatment groups.

103

Phage resistant isolates (%)

B
Phage resistant isolates (%)

A
100
80
60
40
20
0
Control

80
60
40
20
0

Phage

Control

Phage

D
Phage resistant isolates (%)

C
Phage resistant isolates (%)

100

100
80
60
40
20
0
Control

Phage

100
80
60
40
20
0
Control

Phage

Figure 6: Percentage of phage resistant Salmonella Typhimurium isolates recovered from
phage-treated ground pork after incubation at room temperature for 24 h (A) and 48 h (B).
Percentage of phage resistant Salmonella Enteritidis isolates recovered from phagetreated ground pork after incubation at room temperature for 24 h (C) and 48 h (D)* =
statistical differences (P <0.05) in the percentage of phage resistant bacterial isolates
between treatment groups.

104
List of References
Abuladze, T., M. Li, M. Y. Menetrez, T. Dean, A. Senecal, and A. Sulakvelidze. 2008.
Bacteriophages reduce experimental contamination of hard surfaces, tomato,
spinach, broccoli, and ground beef by Escherichia coli O157:H7. Appl. Environ.
Microbiol. 74:6230–6238.
Anany, H., W. Chen, R. Pelton, and M. W. Griffiths. 2011. Biocontrol of Listeria
monocytogenes and Escherichia coli O157:H7 in meat by using phages
immobilized on modified cellulose membranes. Appl. Environ. Microbiol.
77:6379–6387.
Bigwood, T., J. A. Hudson, and C. Billington. 2009. Influence of host and bacteriophage
concentrations on the inactivation of food-borne pathogenic bacteria by two
phages: RESEARCH LETTER. FEMS Microbiol. Lett. 291:59–64.
Carlton, R. M., W. H. Noordman, B. Biswas, E. D. De Meester, and M. J. Loessner. 2005.
Bacteriophage P100 for control of Listeria monocytogenes in foods: Genome
sequence, bioinformatic analyses, oral toxicity study, and application. Regul.
Toxicol. Pharmacol. 43:301–312.
Carter, C. D., A. Parks, T. Abuladze, M. Li, J. Woolston, J. Magnone, A. Senecal, A. M.
Kropinski, and A. Sulakvelidze. 2012. Bacteriophage cocktail significantly
reduces Escherichia coli O157: H7 contamination of lettuce and beef, but does
not protect against recontamination. Bacteriophage 2:178–185.
Chan, B. K., S. T. Abedon, and C. Loc-carrillo. 2013. Phage cocktails and the future of
phage therapy. Future Microbiol.:769–783.

105
Ebner, P. D., and A. G. Mathew. 2000. Effects of antibiotic regimens on the fecal
shedding patterns of pigs infected with Salmonella Typhimurium. J. Food Prot.
63:709–714.
Guenther, S., O. Herzig, L. Fieseler, J. Klumpp, and M. J. Loessner. 2012. Biocontrol of
Salmonella Typhimurium in RTE foods with the virulent bacteriophage FO1-E2.
Int. J. Food Microbiol. 154:66–72.
Guenther, S., D. Huwyler, S. Richard, and M. J. Loessner. 2009. Virulent bacteriophage
for efficient biocontrol of Listeria monocytogenes in ready-to-eat foods. Appl.
Environ. Microbiol. 75:93–100.
Hall, A. R., D. De Vos, V. P. Friman, J. P. Pirnay, and A. Buckling. 2012. Effects of
sequential and simultaneous applications of bacteriophages on populations of
Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ.
Microbiol. 78:5646–5652.
Hong, Y., Y. Pan, and P. D. Ebner. 2014. Meat science and muscle biology symposium:
Development of Bacteriophage treatments to reduce Escherichia coli O157:H7
contamination of beef products and produce. J. Anim. Sci. 92:1366–1377.
Hong, Y., Y. Pan, N. J. Harman, and P. D. Ebner. 2014. Complete Genome Sequences of
Two Escherichia coli O157:H7 Phages Effective in Limiting Contamination of
Food Products. Genome Announc.2(5): e00519-14.
Hungaro, H. M., R. C. S. Mendonça, D. M. Gouvêa, M. C. D. Vanetti, and C. L. de O.
Pinto. 2013. Use of bacteriophages to reduce Salmonella in chicken skin in
comparison with chemical agents. Food Res. Int. 52:75–81.

106
Jończyk, E., M. Kłak, R. Międzybrodzki, and A. Górski. 2011. The influence of external
factors on bacteriophages--review. Folia Microbiol. (Praha). 56:191–200.
Kittler, S., S. Fischer, A. Abdulmawjood, G. Glünder, and G. Kleina. 2013. Effect of
bacteriophage application on Campylobacter jejuni loads in commercial broiler
flocks. Appl. Environ. Microbiol. 79:7525–7533.
Kropinski, A. M., T. Waddell, J. Meng, K. Franklin, H.-W. Ackermann, R. Ahmed, A.
Mazzocco, J. Yates, E. J. Lingohr, and R. P. Johnson. 2013. The host-range,
genomics and proteomics of Escherichia coli O157:H7 bacteriophage rV5. Virol.
J. 10:76.
Leverentz, B., W. S. Conway, Z. Alavidze, W. J. Janisiewicz, Y. Fuchs, M. J. Camp, E.
Chighladze, and A. Sulakvelidze. 2001. Examination of bacteriophage as a
biocontrol method for Salmonella on fresh-cut fruit: a model study. J. Food Prot.
64:1116–1121.
Leverentz, B., W. S. Conway, M. J. Camp, W. J. Janisiewicz, T. Abuladze, M. Yang, R.
Saftner, and A. Sulakvelidze. 2003. Biocontrol of Listeria monocytogenes on
fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin. Appl.
Environ. Microbiol. 69:4519–4526.
Loc-Carrillo, C., and S. T. Abedon. 2011. Pros and cons of phage therapy. Bacteriophage
1:111–114.
Scallan, E., R. M. Hoekstra, F. J. Angulo, R. V Tauxe, M.-A. Widdowson, S. L. Roy, J. L.
Jones, and P. M. Griffin. 2011. Foodborne illness acquired in the United States-major pathogens. Emerg. Infect. Dis. 17:7–15.

107
Sharma, M., J. R. Patel, W. S. Conway, S. Ferguson, and A. Sulakvelidze. 2009.
Effectiveness of bacteriophages in reducing Escherichia coli O157:H7 on freshcut cantaloupes and lettucet. J. Food Prot. 72:1481–1485.
Spricigo, D. A., C. Bardina, P. Cortés, and M. Llagostera. 2013. Use of a bacteriophage
cocktail to control Salmonella in food and the food industry. Int. J. Food
Microbiol. 165:169–174.
Thiel, K. 2004. Old dogma, new tricks--21st Century phage therapy. Nat. Biotechnol.
22:31–36.
Wall, S. K., J. Zhang, M. H. Rostagno, and P. D. Ebner. 2010. Phage therapy to reduce
preprocessing Salmonella infections in market-weight swine. Appl. Environ.
Microbiol. 76:48–53.
Zhang, J., Y. Hong, N. J. Harman, A. Das, and P. D. Ebner. 2014. Genome sequence of a
Salmonella phage used to control salmonella transmission in Swine. Genome
Announc. 2.
Zhang J., Y. Hong, M. Fealey, A. Singh, K. Walton, C. Martin, N. J . Harman, J. Mahlie,
and P. D. Ebner. 2015. Physiological and molecular characterization of
Salmonella bacteriophages previously used in phage therapy. J. Food Prot. (in
press)

108

CHAPTER 5. THE IMPACT OF ORAL ADMINISTERED PHAGES ON HOST:
ACUTE IMMUNE RESPONSES AND GUT MICROBIOME

5.1

Abstract

Extensive studies have shown the efficacy of phage therapy in reducing the
carriage of foodborne pathogens in food animals. Far fewer studies have focused on the
safety of phage therapy, especially in terms of how high concentrations of phage
challenges may elicit animal acute response and affect the gut microbiome. Here we
administered E. coli O157:H7 phages to mice (n = 12) at either low (105 PFU) or high
(107 PFU) concentration. At 6 h and 24 h post treatment, blood and fecal samples were
collected to measure the levels of 12 pro-inflammatory cytokines (IL1A, IL1B, IL2, IL4,
IL6, IL10, IL12, IL17A, IFNγ, TNFα, G-CSF, and GM-CSF) as well as intestinal IgA
and IgG. To test the effect of phages on animal gut microbiome, three-week-old pigs
were administered a standard diet containing ASP 250 (chlortetracycline, sulfamethazine,
and penicillin; n = 5), a standard diet with daily inoculation of 5×1010 PFU of phages via
oral gavage (N=6), and a standard diet without antibiotics or phage (control; n = 6). After
two weeks, pigs were euthanized, microbial DNA of ileal, cecal, and fecal contents was
extracted, and the microbiome composition was analyzed using 16S rRNA. Our results
showed no differences in the levels of intestinal IgA and IgG among control, low phage,
and high phage groups at both 6 h and 24 h post treatment. However, phage treatment did
elicit some cytokine response, with the levels of G-CSF at 6 h post-low phage treatment,
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levels of G-CSF, IL1A, IL1B, IL10, and IL17A at 6 h post-high phage treatment, levels
of IL17A, IFNα, G-CSF, and GM-CSF at 24 h post-low phage treatment, and levels of
IL1A, IL2, IL10 and G-CSF at 24 h post-high phage treatment being significantly higher
(P < 0.05) than corresponding cytokine levels in control group. All cytokine
concentrations, however, were within normal ranges for mice at all sampling times across
all treatments. In pig experiments, no performance differences (ADG, WG, F:G) were
observed among control, antibiotic, and phage groups. However, antibiotic treated pigs
had numerically higher WG than pigs in the other treatments in the second week (4.5 kg
in antibiotic group compared to 3.67 kg in control and 3.6 kg phage-treated group, P=
0.0834). The differences in both phylogeny and relative taxon abundance were accounted
for microbiome composition comparison. Compared to control microbiome, the antibiotic
treatment significantly altered the microbiome composition at ileum (P<0.05), with the
Bacilli class being mostly affected (22% in antibiotic group vs. 76% in control, FDR =
0.0572). No significant differences were observed in cecal and fecal microbiome between
control and antibiotic-treated pigs. Compared to control, phage treatment did not alter the
composition of the gut microbiome at any of the tested intestinal compartments.
Significant abundance differences were observed at the OTU level, with OTUs belonging
to genera such as Lactobacillus and Streptococcus being over or underrepresented in
either antibiotic or phage treated groups compared to controls. Determining whether these
changes are deleterious to host, however, requires further studies. Taken together, our
study indicated that phage administrations, even at high concentrations, would not elicit
adverse acute immune response or greatly alter gut microbiome.
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5.2

Introduction

Recently, there has been regained interest in the development of phage-based
antibacterials. Extensive studies have focused on measuring the efficacy of phage therapy
in preventing or reducing undesired bacteria in food animals, food processing facilities,
medical environments, and even humans. In agriculture, phage therapy has showed
effective in reducing various foodborne pathogens, such as Salmonella in swine (Wall et
al., 2010) and poultry (Atterbury et al., 2007), Campylobacter in poultry (Loc Carrillo et
al., 2005), and E. coli O157:H7 in ruminants (Rozema et al., 2009).
Compared to many other antimicrobial strategies, especially antibiotic treatments,
phage therapy has the unique advantage of being highly specific. It is common for phages
to only affect only specific bacterial serovars or even strains within a serovar. (LocCarrillo and Abedon, 2011). As such, it is generally believed that, phages, even when
applied in high concentrations via oral delivery, have limited collateral effect on
untargeted bacteria and, as a result, are less likely to cause the microbial imbalances that
are commonly observed as a side effects in antibiotic treatments. However, few studies,
especially those using culture-independent techniques, have evaluated the impact of
phages on gut microbiome.
It is well established that the gut microbiome plays essential roles in animal
growth and health. With the recent advance in 16S rRNA analysis and metagenomic
analysis, it is clear that altered gut microbiome can significantly impact different
metabolic and immunologic functions. Therefore, it is essential to more comprehensively
evaluate the impact of phage therapy on host gut microbiome. Additionally, the extent to
which phages to elicit host acute immune response remains understudied as well. While

111
animals are constantly exposed to phages in natural environment, much higher
concentrations of phages are commonly used in phage therapy. Thus, it is equally
important to evaluate whether phage challenge at high concentrations induces any
adverse immune response to the animal host. In this study, the impact of phages on host
animals was carefully characterized in terms of both host acute immune response and gut
microbiome.
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5.3

Materials And Methods
5.3.1

Bacteriophages

An E. coli O157:H7 phage cocktail containing three unrelated phages was used to
measure the acute immune response to phage treatment in a mouse model. A previous
study demonstrated that the same phage cocktail was effective in reducing E. coli
O157:H7 contamination in ground beef and spinach (Hong et al., 2014). Each phage was
propagated separately and combined in equal amount. The titer of the phage mixture was
determined by plaque assay and then diluted to solutions of 108 PFU/mL (high phage
group) and 106 PFU/mL (low phage group).
A ten-Salmonella phage cocktail was used to evaluate the impact of orally
administrated phages on animal gut microbiome in a pig model. The same phage cocktail
was effective in controlling lairage-associated Salmonella infection in pigs (Wall et al.,
2010; Saez et al., 2011). Similarly, each phage was propagated separately and combined
in equal amount. The final concentration of mixed phage cocktail was 1.07 x 1010
PFU/mL.

5.3.2

Mice Immune Responses to Phage Treatment

All animal experiments were approved by the Purdue University Animal Care and
Use Committee (PACUC). Thirty-six BALB/c mice (18 males and 18 females; 5-weekold) were treated with 2 g/L of streptomycin (Sigma-Aldrich, MO) in drinking water for
3 d. Mice were then divided into 3 groups (6 male and 6 female mice per group) and
subjected to feed withdrawal for 24 h before phage treatment. Mice in the high phage
group received 100 ul of E. coli O157:H7-phage cocktail at a concentration of 108
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PFU/mL; mice in the low phage group received 100 ul of same phage cocktail at a
concentration of 106 PFU/mL; and mice in control group received 100 ul of 1x PBS. All
treatments were delivered via oral gavage. At 6 h and 24 h post phage treatment, feces
and blood (submandibular) were collected from each mouse. Blood samples were
centrifuged at 1,500 x g to separate plasma from blood cells. Plasma samples were
immediately used to measure the concentrations of 12 pro-inflammatory cytokines (IL1A,
IL1B, IL2, IL4, IL6, IL10, IL12, IL17A, IFNγ, TNFα, G-CSF, and GM-CSF) using a
mouse inflammatory cytokines multi-analyte ELISArray kit (SABiosciences, Valencia,
CA). Fecal samples were used to measure the levels of intestinal IgA and IgG using a
mouse IgA, IgG ELISA Quantitation set (Bethyl Laboratories, Montgomery, TX)
according to the manufacturer’s instructions.

5.3.3

Impact of Phage Therapy on Pig Gut Microbiome

Seventeen, three-week-old pigs were obtained from a high health commercial
farm. Sows were not administered antibiotics post-farrowing and pigs were not exposed
to antibiotics in their nursery diet or creep feed before arrival. Upon arrival, pigs were
housed in the same pen for one week as an adjustment period before they were assigned
to one of the three treatments: control group (n = 6) where pigs received only basal diet,
phage group (n = 6) where pigs received basal diet plus daily inoculation of 5 ml
Salmonella-phage cocktail at a concentration of 1.07 x 1010 PFU/mL via oral gavage, and
antibiotic group (n = 5) where pigs received basal diet supplemented with an antibiotic
premix ASP 250 (100 g chlortetracycline, 100 g sulfamethazine, and 50 g penicillin per
ton of feed, Zoetis, Florham Park, NJ). Pigs were housed individually with each pen
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equipped with separate feed and water systems. The three treatment groups were
maintained at three separated regions of the animal house to prevent cross-contamination.
All pigs were weighted weekly and feed intake and health status were recorded daily.
After two weeks of treatment, all pigs were euthanized with captive bolt gun and ileal
contents, cecal contents and fecal samples were collected.
Microbial DNA of each intestinal sample was extracted using a FastDNATM spin
kit for soil (MP Biologicals, Santa Ana, CA) following the manufacturer’s protocol. For
samples with high liquid content, liquid was removed by centrifugation at 10,000 x g for
10 min before the suggested amount of sample was measured for DNA extraction. DNA
samples were quantified using QuantiFluor® dsDNA system (Promega, Madison, WN),
assessed for DNA integrity by gel electrophoresis, and stored at -20 °C before use.
The construction of the 16S rRNA library was carried out in two steps. First, the
V3 to V4 region of bacterial 16S rRNA gene was amplified using universal primers 338F
(5’-ACTCCTACGGGAGGCAGC) and 806R (5’-GGACTACHVGGGTWTCTAAT)
(Fadrosh et al., 2014) containing Illumina adapter sequences and a cycling program of: 1)
one cycle of 94 °C for 5 min; 2) 25 cycles of 94 °C for 30s, 60 °C for 30 s and 72 °C for
30 s; and 3) a final cycle of 72 °C for 5 min. Each PCR included 25 ul KAPA HiFi
hotstar readymix, 2X (Kapa Biosystems, Wilmington, MA), 10 uM of each primer, 1 ng
of template DNA, 0.5 mg/ml BSA (bovine serum albumin, Sigma-Aldrich, St. Louis,
MO), and sterile ddH2O to a final volume of 50 ul. The resulting amplicon was purified
using the Agencourt AMPure XP PCR purification system (Beckman Coulter, Pasadena,
CA). Illumina 8x12 TruSeq dual index sequencing primers (Illumina, San Diego, CA)
were used to barcode individual samples in second PCR using a cycling program of:
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1) one cycle of 94 °C for 3 min; 2) eight cycles of 94 °C for 30 s, 64 °C for 30 s and
72 °C for 30 s; and 3) a final cycle of 72 °C for 5 min. Each PCR reaction included 25 ul
KAPA HiFi hotstar readymix, 2X (Kapa Biosystems, Wilmington, MA), 10 uM of each
primer, 5 ul of purified amplicon of first PCR, and sterile ddH2O to a final volume of 50
ul. The resulting amplicon was purified by gel electrophoresis and gel extraction using
QIAquick Gel Extraction kit (Qiagen, Venlo, Netherlands). The final amplicon of each
sample was quantified using QuantiFluor® dsDNA system (Promega, Madison, WN) and
mixed in equal amounts and sequenced as a 16S rRNA library with the Illumina Miseq
platform (2 x 300 bp).
Sequence reads were sorted by barcodes, quality filtered, and adapter-trimmed.
The reads sequenced from 5’-end and 3’-end were merged based on the overlapping
sequences and a total of 37,891 to 547,061 merged reads were obtained for each samples.
Due to the difference in total number of reads among samples, relative abundance was
used. QIIME (Version 1.8.0, Caporaso et al., 2010) was used to analyze and compare the
microbiome between samples. All merged reads underwent operational taxonomic unit
(OTU) picking, taxonomic assignment and phylogenetic tree construction using Green
Genes (97, 13_5 version) as a reference database. Weighted UniFrac distance matrices,
accounting for differences in both phylogeny and relative taxon abundance, were
generated and compared pairwise between treatments within each intestinal compartment
using ANOSIM. The relative abundance difference at taxonomic and OTU levels was
also compared pairwise between treatments within each intestinal compartments using
phyloseq software package (McMurdie and Holmes, 2013) and a FDR (false discovery
rate) of 0.05 was used to determine statistical significance.
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5.3.4

Statistical Analysis

For mouse experiments, IgG and IgA concentrations were compared among
treatment groups using a one-way ANOVA and also compared between male and female
mice within treatment groups using a two-sample t-test of the SAS TTEST procedure.
Percentages of mice with elevated immune responses were compared among control, low
phage, and high phage groups by a Chi-square test using the SAS FREQ procedure. For
pig experiments, the growth performance data were compared among three groups using
a one-way ANOVA.
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5.4
5.4.1

Results

Immune Responses of Mice to Phage Treatment

All mice remained healthy throughout the experiment. Intestinal IgG and IgA
were compared among control, low phage, and high phage groups, and also compared
between male and female mice within treatment groups. Bacteriophages were detected in
fecal samples at 6 h but not 24 h post phage treatment (data not shown). At 6 h post
phage treatment, total IgA and IgG did not differ among the groups (Fig. 1A and 2A).
Similar results were observed at 24 h post phage administration (Fig. 1B and 2B).
However, effects of gender in the immune response were identified in the high phage
treated group at 6 h post phage treatment. Higher levels of IgA and IgG in female mice
were detected than in the male mice (Fig. 1C and 2C). The effect was not observed at 24
h post treatment in high phage group (Fig. 1D and 2D). Intestinal IgA was also higher in
control female mice at 24 h post treatment than in control male mice (Fig. 1D).
Among the 12 cytokines tested at 6 h and 24 h post treatment, most cytokines did
not show significant differences between phage treated mice and controls. However, at 6
h post treatment, G-CSF in low phage treated mice and G-CSF, IL1A, IL1B, IL10 and
IL17A in high phage treated mice were significantly (P < 0.05) higher than those in
control mice. At 24 h post treatment, IL17A, IFNα, G-CSF and GM-CSF in low phage
treated mice and IL1A, IL2, IL10 and G- CSF in high phage treated mice were higher
(P<0.05) than those in control mice. All cytokine levels, however, were in the normal
range for mice in all treatment groups at all sampling points.
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5.4.2 Pig Growth Performance
All pigs, except one in the phage group, remained healthy throughout the
experiment. The pig showed mild diarrhea before the experiment and sporadic diarrhea
throughout the experiment. Therefore, both the growth performance data and the 16S
rRNA sequences generated from that pig were not used.
Pig growth performance, in terms of average daily feed intake (ADF), weekly
weight gain (WG) and feed/gain ratio (F/G), was not different (P > 0.05) among control,
phage, and antibiotic groups (Table 1). However, pigs in the antibiotic group had a
tendency to have higher WG than pigs in the other two groups at second week of
experiment (4.5 kg in antibiotic group compared to 3.67 kg in control and 3.6 kg phage
group, P= 0.0834).

5.4.3

Gut Microbiome Analysis and Comparison

It was consistent across the animals, regardless of treatments, that Firmicutes and
Proteobacteria were the most abundant phyla in the ileal microbiome of pigs, accounting
for approximately 85% and 14% of reads, respectively. Firmicutes, Bacteriodetes, and
Proteobacteria were the top three abundant phyla in the cecal content microbiome,
accounting for 56%, 31%, and 11% of reads, respectively, and in the fecal microbiome as
well, counting for 58%, 26%, and 11% of reads, respectively (Fig. 3).
Microbial communities were compared pairwise between treatments within each
intestinal compartment. Weighted UniFrac distance matrices, which account for
differences in both phylogeny and relative taxon abundance, were used as inputs and
ANOSIM were used as the statistical method. The ileal microbiome of antibiotic treated

119
pigs was statistically different from that of control pigs (P = 0.049); however, differences
were not observed in either the cecal (P = 0.123) or fecal (P = 0.348) microbiome
between the two treatments. No differences were detected in the ileal (P = 0.12), cecal (P
= 0.331) or fecal (P = 0.732) microbiome between phage treated pigs and controls. No
relative abundance differences were observed between treatments at taxonomic levels.
There were numerically less Bacilli class in antibiotic treated ileal microbiome compared
to the control ileal microbiome (22% vs. 76%, FDR = 0.0572), and numerically less
Actinobacteria (5.67 x 10-4% vs. 4.4 x 10-3%, FDR = 0.0582) and Bacilli (4% vs. 18%,
FDR = 0.0582) classes in the antibiotic treated cecal microbiome than in the phage
treated cecal microbiome. Significant relative abundance differences were only observed
at the OTU level, with OTUs associated with various bacteria being over or
underrepresented in either antibiotic (Fig. 5) or phage treated group (Fig. 4) compared to
control at all three intestinal compartments.
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5.5

Discussion

Phage therapy has shown great promise in preventing or reducing the carriage of
foodborne pathogens in agriculture animals. To better assess the safety of phage therapy
and understand the outcome of oral phage treatments at high concentrations to applied
animals, this study evaluated the impact of phages on host acute immune responses and
the gut microbiome.
In our experiments, we observed that orally administrated phages did elicit some
cytokine responses in mice, but the cytokine levels were in the normal ranges of healthy
mice (Stenina et al., 2012). Additionally, we found that there were no differences in
intestinal IgA and IgG among treatment groups after 24 h post treatment. This may be
due to the clearance of phage from the intestine, as phages were not recovered after 24 h
post treatment. It should also be noted that 24 h may not be enough time to detect an
appreciable humoral immune response. In order to more accurately describe the immune
response pattern of mice, multiple sampling points over longer sampling periods may be
needed. Interestingly, at 6 h post treatment, female mice had higher levels of intestinal
IgA and IgG than male mice. This phenomenon may be due to stronger and longer lasting
immune response in female mice (Ansar Ahmed et al., 1985). In accord with our results,
a recent phage safety test performed on 15 healthy human adults demonstrated that oral
phage administration did not elicit appreciable levels of phage-specific IgG, IgM, and
IgA (Bruttin and Brüssow, 2005). While these results provide some evidence that phages
by themselves are not likely to elicit adverse acute immune response, extra consideration
must be taken when phage-targeting bacteria are also presented, in which case, the lysis
of bacterial cells could lead to a sudden increase of endotoxins in the host and
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consequently lead to extensive acute immune response, or even death in animals
(Boratynski et al., 2004).
Our study also investigated the impact of phage treatment on pig gut microbiome.
One pig in control group and one in phage group failed to yield ileal samples due to lack
of ileal content during collection. Additionally, sequence reads of all three intestinal
samples collected from the aforementioned diarrhea pig in phage group and those of the
ileal sample collected from a pig in antibiotic group were not included in analysis.
Diarrhea was considered to have an effect on gut microbiome. With a rapid passage of
lumen content through the intestine, the diarrhea cecal and fecal microbiome resembled
more closely to ileal microbiome composition than the cecal or fecal microbiome
compositions of healthy pigs (data not shown). The ileal microbiome of antibiotic group
was removed due to its abnormal high percentage of Proteobacteria (98.52%).
In general, the gut microbiome, regardless of treatments, resembled the typical
swine microbiome shown previously. For example, consistent with previous fecal
microbiome studies (Lamendella et al., 2011; Looft et al., 2012; Looft et al., 2014), the
fecal microbiome of this study was dominated by bacteria belong to Firmicutes,
Batereroidetes, and Proteobacteria phyla, with Prevotella being the most abundant genus
in Bacteroidetes phylum. Meanwhile, the cecal microbiome had similar composition as
the fecal microbiome, while the ileal microbiome was almost exclusively dominated by
Firmicutes and Proteobacteria. These results are consistent with another study that
characterized the microbiome at different intestinal compartments in swine (Looft et al.,
2014).
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Our results showed that phage treatment did not alter the overall composition of
the gut microbiome at any tested gut compartments (ileum, cecum, colon). Similar results
were also reported in a recent human study, where the oral administration of an E. coli
phage cocktail in healthy adults at doses as high as 3 x 109 PFU did not result in
consistent changes in the fecal microbiome when compared to adults receiving a placebo
(Sarker et al., 2012). The conservation of gut microbiome under phage challenge
provided experimental evidence to the previous assumption that phages are highly host
specific and have limited affect on untargeted gut microbiome. It is notable that both
studies were conducted under conditions where animals or humans were not infected with
phage-targeting bacteria. This reflects a common phage application condition in practice,
especially in agricultural uses, where phages are mostly designed for preventative
interventions. On the other hand, a recent study evaluated the impact of phages on the
mouse gut microbiome during infection where mice were colonized with an
extraintestinal, pathogenic E. coli. Treatment with a phage cocktail effectively reduced
the amount of challenge E. coli in the intestine without significantly affecting the
surrounding microbiome at family levels using 16S rRNA anaylsis (Sordi et al., 2015,
Poster communication, 21st Evergreen International Phage Meeting). Unlike the
extraintestinal E. coli in the aforementioned study, many foodborne pathogens are
commensal bacteria in agriculture animals, possibly having an established niche in gut
microbiome. In addition, for better application flexibility, phage cocktails designed for
agriculture uses probably have broad host spectrum. Therefore, there remain some
unanswered questions regarding the impact of phages on the gut microbiome of infected
animals under agriculture settings.
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Compared to the control, no consistent relative abundance changes were observed
in the phage treated microbiome at any tested intestinal compartments. Significant
abundance increase or decrease in the phage treated microbiome compared to the control
microbiome was only observed at OTU level at all intestinal compartments. Deeper
sequencing and improvement in 16S rRNA annotation in reference databases could
enhance the OTU taxonomic assignment and therefore possibly provide a better idea of
whether abundance changes of certain OTUs reflect abundance changes in certain
bacterial genera or species. Likewise, further experiments are required to determine
whether such changes are deleterious to animals.
Conversely, as was seen in related studies (Collier et al., 2003; Rettedal et al.,
2009; Looft et al., 2012), feeding the antibiotic growth promoter (ASP250) significantly
altered the gut microbiome in pigs with the biggest impact in the ileum. The alteration in
the antibiotic treated ileal microbiome was mainly driven by the relative abundance
decrease in Bacilli class. Lactobacillus was one of the most affected genera in Bacilli
class, with 21 OTUs assigned to Lactobacillus showing significant abundance decrease in
the antibiotic group. This was consistent with previous findings that feeding antibiotic
growth promoters significantly affected Lactobacilli population (Lin, 2011). However,
both abundance increase and decrease have been reported in Lactorbacillus species in
responding to different antibiotic treatments (Rettedal et al., 2009)(Lin, 2011), which
partly explains the fact that significant abundance changes were only observed at the
OTU level and not the genus level. Additionally, previous studies showed significant
abundance decreases in Streptococcus (Looft et al., 2014) and Turicibacter (Rettedal et
al., 2009) of the antibiotic-treated pig ileal microbiome. Significant abundance decreases
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in OTUs associated with each genus were observed in this study. It was noticed that one
antibiotic treated ileal microbiome, compared to the rest antibiotic treated ileal
microbiome, deviated less from the control ileal microbiome. Interestingly, growth
performance analysis indicated that the corresponding animal had significantly lower
feed intake than the rest of animals in antibiotic group, which explains less antibiotic
effect on ileal microbiome. No antibiotic-induced alteration was observed in either cecum
or feces. Besides the fact that ileum was the first site exposed antibiotics, the much less
complex composition of ileal microbiome, compared to that of cecal and fecal
microbiome, likely rendered the ileal microbiome more susceptible to alterations.
The antibiotic-induced alteration of gut microbiome is considered one of the
fundamentals that contribute to antibiotic growth promotion effect. One possible
explanation is that feeding antibiotics could reduce total bacterial load, and, consequently,
reduce microbial nutrient utilization as well as the energy expended by the immune
system in maintaining microbiome homeostasis. In our experiment, antibiotic treated pigs
had numerically higher (P = 0.0834) weight gain than control and phage groups at second
week. The lack of significant growth promotion could be due to a short experiment
period and the fact that pigs in this study were housed in a very clean and bio-controlled
environment, which has previously been shown to reduce growth promoting effects of
antibiotics (Cromwell, 2002).
Taken together, our studies evaluated the potential of oral administrated phages,
at high concentrations, to elicit host acute immune responses and affect microbiome at
different intestinal compartments. While phage treatment did elicit some cytokine
responses, no adverse acute immune response was observed in mice. Meanwhile,
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compared to untreated pigs, no significant composition changes or taxonomic abundance
changes were observed after phage treatment; in contrast, antibiotic treatment resulted in
significant composition changes in the ileal microbiome. While significant abundance
changes were observed at some OTUs, further studies will be needed to determine
whether such changes are deleterious to animal host. Additionally, metagenomic analysis
on the gut microbial DNA samples may further reveal whether phage treatment is
associated with changes in certain functional genes and is considered for future studies.
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5.6

Note

Jiayi Zhang contributed to the study of evaluating the impact of oral administered
phages on host acute immune responses and the results were also included in his Ph.D.
dissertation.
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Figure 1. Intestinal IgA concentrations of all mice and mice of different sex, respectively,
at 6 h (A and C) and 24 h (B and D) after phage administration. * =significant difference
(P<0.05).
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Figure 2. Intestinal IgG concentrations of all mice and mice of different sex, respectively,
at 6 h (A and C) and 24 h (B and D) after phage administration. *=significant difference
(P<0.05).

Figure 3. The composition of ileal, cecal and fecal microbiome of pigs at order level. Treatments within each intestinal
compartment were arranged as, from left to right, control, phage treatment, and antibiotic treatment.
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Figure 4. OTUs of significant abundance changes in the phage treated ileal (A), cecal (B)
and fecal (C) microbiome compared to that in the corresponding control microbiome.
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Figure 5. OTUs of significant abundance changes in the antibiotic treated ileal (A), cecal
(B) and fecal (C) microbiome compared to that in the corresponding control microbiome.
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Table 1: The growth performance of pigs, including average daily feed intake (ADF),
weekly weight gain (WG), and feed/gain ration (F/G) during the two week of experiment.

W1

W2

Control

Phage

Antibiotics

P-value

ADF

0.68

0.66

0.67

0.9901

WG

3.33

3.70

4.20

0.2784

F/G

1.44

1.27

1.13

0.2132

ADF

0.77

0.84

0.98

0.4163

WG

3.67

3.60

4.50

0.0834

F/G

1.53

1.65

1.52

0.7222
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CHAPTER 6. GENERAL CONCLUSIONS

The main objective of this study is to develop phage-based food safety
interventions to reduce contamination of food by two common foodborne pathogens, E.
coli O157:H7 and Salmonella, from “farm to fork”. In this study, the antibacterial
efficacy of phage treatments was tested in different food matrices, under different
conditions, as well as in both phage cocktail and single phage forms. Additionally, this
study also examined phage genome sequences, bacterial phage resistance, and the impact
of orally administrated phages on animal acute immune response and gut microbiome in
effort to more clearly assess the safety and long-lasting efficacy of phage treatments.
Both the second and fourth chapters have demonstrated the efficacy of phage
treatment in reducing bacterial pathogens in various food matrices. In chapter two, the
capacity of a three-phage cocktail to reduce the contamination of E. coli O157:H7 in
ground beef (room temperature for 24h, refrigeration for 24h, and undercooked
condition), spinach, and cheese slices (room temperature for 24h, 48h, and 72h for both
spinach and cheese slices) was tested. In chapter four, the ability of a single-broadspectrum phage to reduce Salmonella serovars in ground pork and liquid eggs (room
temperature for 24h and 48h and refrigeration for 24h, 1w and 2w) was tested. While
both experiments demonstrated the potential of phage treatments as antibacterial
interventions in foods, the results also showed that: 1) food matrices could interfere
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greatly with phage treatments; and 2) temperature could affect the efficacy of phage
treatment. The effects of food matrix observed in this study were two-fold. In chapter two,
it was showed that phage treatment significantly reduced the levels of E. coli O157:H7 in
phage treated ground beef and spinach, but not in cheese slices. And in chapter four, it
was shown that after treatment at room temperature for two days, phage treatment
resulted in an emergence of phage resistant Salmonella in liquid eggs, but not in ground
pork. The food matrix effect, either in terms of efficacy or the development of phage
resistance, could be associated with the differences in food composition, structure, and
production processes. Meanwhile, experiments also showed that treatments with either
the E. coli O157:H7 phage cocktail or the Salmonella single, broad-spectrum phage were
more effective at room temperature, which was more close to the optimal growth
temperature of host bacteria, than at refrigeration.
Whole genome annotation is considered an essential step in phage
characterization and can provide information of phages at the molecular level and help
ensure the absence of undesired genes. The genome sequences of several Salmonella
phages have been characterized previously (Zhang et al., 2014). In chapter three, the
genome sequences of two E. coli O157:H7 phages used in chapter one were characterized.
Phages vB_EcoM_FFH_1 and vB_EcoM_FFH_2 had genome lengths of 108,483 bp and
139,020 bp, respectively. Based on sequence homology, FFH_1 was classified as a T5like phage and FFH_2 was classified as an rV5-like phage. No undesired genes, including
genes coding for antibiotic resistance, toxins, virulence, or lysogeny, were observed in
either E. coli phage genomes. However, 108 out of 160 predicted genes in FFH_1 and
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163 out of 220 predicted genes in FFH_2 did not match to any genes with characterized
functions in NCBI database.
The development of phage resistance is generally considered one of the obstacles
preventing phage application being widely used in practice (Tanji et al., 2004). In chapter
two, several phage resistant E. coli O157:H7 strains were characterized in terms of phage
resistant mechanisms, in vitro stability of phage resistance, and potential fitness losses.
Different resistance mechanisms were observed among phage resistant bacterial strains.
Unlike in some other studies (O’Flynn et al., 2004; Scott et al., 2007), where phage
resistant strains quickly reverted to susceptibility after the absence of phages, all three
resistant strains of this study remained resistant to corresponding phages after a four-day
in vitro sub-culturing. Meanwhile, no significant reductions in bacterial growth or
adhesion to mammalian intestinal cells were observed in any resistant strains. While it is
possible that, in practice, fitness loss could still result in the out-competition of phage
resistant strains due to limited nutrients and more complex microbial community in the
environments where phage treatments are commonly applied, the results of this study
indicated that the emergence of phage resistant bacteria could interfere with the efficacy
of phage treatments, and therefore, mitigation strategies should be developed. One
potential mitigation strategy is the use of phage cocktails consisting of several distinct
phages, as it is much less likely for bacteria to develop resistance to multiple, unrelated
phages simultaneously. While phage resistance was not tested after the treatment with the
three-phage cocktail against E. coli O157:H7 (Chapter two), as expected, high
percentages of phage resistant Salmonella colonies were observed after treatment with
single-broad-spectrum Salmonella phage, at least in liquid eggs (Chapter four).
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While extensive studies have been conducted examining phage efficacy, far fewer
studies are available demonstrating the impact of phage treatments on animal acute
immune responses and the gut microbiome. In Chapter five, acute immune responses
were measured in mice treated with both a low amount of phages (105 PFU), and a high
amount of phages (107 PFU). No differences were observed in the levels of intestinal IgA
and IgG among different treatment groups at 6 h or 24 h post treatment. Phage treatments
did elicit some cytokine response, however, all cytokine concentrations were within
normal ranges for mice at all sampling times across all treatments. The gut microbiome at
the ileum, cecum and feces were also characterized using 16S rRNA sequencing in pigs
receiving control (basal nursery diet), phage treatment (basal diet with daily inoculation
of 5 x 1010 PFU phages via oral gavage) and antibiotic treatment (basal diet supplemented
with antibiotic premix ASP 250) for two weeks. While antibiotic treatment significantly
altered the ileal microbiome compared to control, no consistent changes were observed
between the phage treated microbiome and the control microbiome, in either the overall
microbiome composition or the relative taxonomic abundance. Relative abundance
differences, however, were observed with certain OTUs between the phage treated and
control microbiomes at three intestinal compartments and further studies are needed to
determine whether these changes are deleterious to host.
Taken together, this study demonstrated the potential of phage treatments as
antibacterial interventions in various foods. Phage resistant bacteria, however, were
recovered after treatment using single-broad-spectrum phages in liquid eggs. The
characterization of phage resistant E. coli O157:H7 strains indicated that the development
of phage resistance may result in only limited fitness loss in resistant strains, and
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therefore, mitigation strategies, such as using phage cocktails, should be considered.
Additionally, this study also showed that phage administration would not elicit adverse
acute immune response or greatly alter the gut microbiome in animals, which provides
more knowledge for the applications of phages in live animals.
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